---
document_datetime: 2025-11-03 14:28:44
document_pages: 78
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/vivlipeg-epar-public-assessment-report_en.pdf
document_name: vivlipeg-epar-public-assessment-report_en.pdf
version: success
processing_time: 77.9028171
conversion_datetime: 2025-12-15 19:44:43.820681
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

Amsterdam, 19 June 2025 EMA/CMHP/212241/2025 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Vivlipeg

International non-proprietary name: pegfilgrastim

Procedure No. EMEA/H/C/006739/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Executive summary...............................................................................7 2. Administrative/regulatory information and recommendations on the                             | 1. Executive summary...............................................................................7 2. Administrative/regulatory information and recommendations on the                             | 1. Executive summary...............................................................................7 2. Administrative/regulatory information and recommendations on the                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| procedure....................................................................................................8                                                                                       | procedure....................................................................................................8                                                                                       |                                                                                                                                                                                                      |
| 2.1.                                                                                                                                                                                                 | Scientific advice and protocol assistance                                                                                                                                                            | ...............................................................8                                                                                                                                     |
| 2.2.                                                                                                                                                                                                 | Eligibility to the centralised procedure                                                                                                                                                             | ..................................................................8                                                                                                                                  |
| 2.3.                                                                                                                                                                                                 | Legal basis, dossier content and multiples.............................................................8                                                                                             |                                                                                                                                                                                                      |
| 2.4.                                                                                                                                                                                                 | Information on paediatrics                                                                                                                                                                           | ..................................................................................8                                                                                                                  |
| 2.5.                                                                                                                                                                                                 | Information on orphan market exclusivity                                                                                                                                                             | .............................................................9                                                                                                                                       |
| 2.5.1.                                                                                                                                                                                               | Similarity with authorised orphan medicinal products...........................................9                                                                                                     |                                                                                                                                                                                                      |
| 2.6.                                                                                                                                                                                                 | Steps taken for the assessment of the product                                                                                                                                                        | ......................................................9                                                                                                                                              |
| 2.7.                                                                                                                                                                                                 | Final CHMP outcome...........................................................................................9                                                                                       |                                                                                                                                                                                                      |
| 2.7.1.                                                                                                                                                                                               | Considerations related to orphan market exclusivity                                                                                                                                                  | ............................................9                                                                                                                                                        |
| 2.7.2.                                                                                                                                                                                               | Final opinion...................................................................................................9                                                                                    |                                                                                                                                                                                                      |
| 2.7.3.                                                                                                                                                                                               | Conclusions on biosimilarity and benefit risk balance                                                                                                                                                | .........................................10                                                                                                                                                          |
| 2.7.4.                                                                                                                                                                                               | Conditions or restrictions regarding supply and use                                                                                                                                                  | ...........................................10                                                                                                                                                        |
| 2.7.5.                                                                                                                                                                                               | Other conditions and requirements of the marketing authorisation                                                                                                                                     | ......................10                                                                                                                                                                             |
| 2.7.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product 10 2.7.7. Conditions or restrictions with regard to the safe and effective use of the medicinal | 2.7.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product 10 2.7.7. Conditions or restrictions with regard to the safe and effective use of the medicinal | 2.7.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product 10 2.7.7. Conditions or restrictions with regard to the safe and effective use of the medicinal |
| 3.                                                                                                                                                                                                   | Introduction........................................................................................11                                                                                               |                                                                                                                                                                                                      |
| 3.1.                                                                                                                                                                                                 | Therapeutic context..........................................................................................11                                                                                      |                                                                                                                                                                                                      |
| 3.2.                                                                                                                                                                                                 | Aspects of development....................................................................................11                                                                                         |                                                                                                                                                                                                      |
| 3.3.                                                                                                                                                                                                 | Description of the product.................................................................................11                                                                                        |                                                                                                                                                                                                      |
| 3.4.                                                                                                                                                                                                 | Inspection issues                                                                                                                                                                                    | .............................................................................................11                                                                                                      |
| 3.4.1.                                                                                                                                                                                               | Good manufacturing practice (GMP) inspection(s)                                                                                                                                                      | .............................................11                                                                                                                                                      |
| 3.4.2.                                                                                                                                                                                               | Good laboratory practice (GLP) inspection(s)                                                                                                                                                         | ....................................................11                                                                                                                                               |
| 3.4.3.                                                                                                                                                                                               | Good clinical practice (GCP) inspection(s).........................................................11                                                                                                |                                                                                                                                                                                                      |
| 4. Quality aspects....................................................................................12                                                                                             | 4. Quality aspects....................................................................................12                                                                                             | 4. Quality aspects....................................................................................12                                                                                             |
| 4.1.                                                                                                                                                                                                 | Introduction                                                                                                                                                                                         | ....................................................................................................12                                                                                               |
| 4.2.                                                                                                                                                                                                 | Active substance..............................................................................................12                                                                                     |                                                                                                                                                                                                      |
| 4.2.1.                                                                                                                                                                                               | General information.......................................................................................12                                                                                         |                                                                                                                                                                                                      |
| 4.2.2.                                                                                                                                                                                               | Manufacture, characterisation, and process controls                                                                                                                                                  | ..........................................12                                                                                                                                                         |
| 4.2.3.                                                                                                                                                                                               | Specification.................................................................................................15                                                                                     |                                                                                                                                                                                                      |
| 4.2.4.                                                                                                                                                                                               | Stability                                                                                                                                                                                            | .......................................................................................................16                                                                                            |
| 4.3. Finished medicinal product................................................................................16                                                                                    | 4.3. Finished medicinal product................................................................................16                                                                                    | 4.3. Finished medicinal product................................................................................16                                                                                    |
| 4.3.1.                                                                                                                                                                                               | Description of the product and pharmaceutical development...............................16                                                                                                           |                                                                                                                                                                                                      |
| 4.3.2.                                                                                                                                                                                               | Manufacture of the product and process controls...............................................17                                                                                                     |                                                                                                                                                                                                      |
| 4.3.3.                                                                                                                                                                                               | Product specification......................................................................................18                                                                                        |                                                                                                                                                                                                      |
| 4.3.4.                                                                                                                                                                                               | Stability of the product                                                                                                                                                                             | ..................................................................................18                                                                                                                 |
| 4.3.5.                                                                                                                                                                                               | Comparability exercise for finished medicinal finished product                                                                                                                                       | ............................19                                                                                                                                                                       |
| 4.3.6.                                                                                                                                                                                               | Post approval change management protocol(s) .................................................22                                                                                                      |                                                                                                                                                                                                      |
| 4.3.7.                                                                                                                                                                                               | Adventitious agents.......................................................................................23                                                                                         |                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| 4.3.8. 4.4.                                                                                               | Medical Device..............................................................................................23 Discussion and conclusions on chemical, pharmaceutical and biological aspects .......23   |                                                                                                        |
|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 5. Non-clinical aspects.............................................................................24    | 5. Non-clinical aspects.............................................................................24                                                                                                   |                                                                                                        |
| 5.1.                                                                                                      | Introduction                                                                                                                                                                                             | ....................................................................................................24 |
| 5.2.                                                                                                      | Analytical methods...........................................................................................24                                                                                          |                                                                                                        |
| 5.3.                                                                                                      | Pharmacology..................................................................................................24                                                                                         |                                                                                                        |
| 5.3.1.                                                                                                    | Pharmacokinetics                                                                                                                                                                                         | ..........................................................................................24           |
| 5.4.                                                                                                      | Toxicology.......................................................................................................24                                                                                      |                                                                                                        |
| 5.4.1.                                                                                                    | Ecotoxicity/environmental risk assessment.......................................................24                                                                                                       |                                                                                                        |
| 5.5.                                                                                                      | Overall discussion and conclusions on non-clinical aspects                                                                                                                                               | ....................................25                                                                 |
| 5.5.1.                                                                                                    | Discussion....................................................................................................25                                                                                         |                                                                                                        |
| 5.5.2.                                                                                                    | Conclusions                                                                                                                                                                                              | ..................................................................................................26   |
| 6. Clinical aspects....................................................................................27 | 6. Clinical aspects....................................................................................27                                                                                                |                                                                                                        |
| 6.1.                                                                                                      | Introduction                                                                                                                                                                                             | ....................................................................................................27 |
| 6.1.1.                                                                                                    | GCP aspects                                                                                                                                                                                              | .................................................................................................27    |
| 6.1.2.                                                                                                    | Tabular overview of clinical trials.....................................................................27                                                                                               |                                                                                                        |
| 6.2.                                                                                                      | Clinical pharmacology.......................................................................................28                                                                                           |                                                                                                        |
| 6.2.1.                                                                                                    | Methods.......................................................................................................28                                                                                         |                                                                                                        |
| 6.2.2.                                                                                                    | Pharmacokinetics                                                                                                                                                                                         | ..........................................................................................28           |
| 6.2.3.                                                                                                    | Pharmacodynamics........................................................................................34                                                                                               |                                                                                                        |
| 6.2.4.                                                                                                    | Overall discussion and conclusions on clinical pharmacology...............................43                                                                                                             |                                                                                                        |
| 6.3.                                                                                                      | Clinical efficacy................................................................................................44                                                                                      |                                                                                                        |
| 6.3.1.                                                                                                    | Dose response study(ies)                                                                                                                                                                                 | ...............................................................................44                      |
| 6.3.2.                                                                                                    | Main study                                                                                                                                                                                               | ...................................................................................................44  |
| 6.3.3.                                                                                                    | Clinical studies in special populations...............................................................56                                                                                                 |                                                                                                        |
| 6.3.4.                                                                                                    | In vitro biomarker test for patient selection for efficacy......................................56                                                                                                       |                                                                                                        |
| 6.3.5.                                                                                                    | Supportive study(ies)                                                                                                                                                                                    | ....................................................................................56                 |
| 6.3.6.                                                                                                    | Analysis performed across trials (pooled analyses and meta-analysis)                                                                                                                                     | .................56                                                                                    |
| 6.3.7.                                                                                                    | Overall discussion and conclusions on clinical efficacy ........................................56                                                                                                       |                                                                                                        |
| 6.4.                                                                                                      | Clinical safety..................................................................................................57                                                                                      |                                                                                                        |
| 6.4.1.                                                                                                    | Safety data collection                                                                                                                                                                                   | ....................................................................................57                 |
| 6.4.2.                                                                                                    | Patient exposure                                                                                                                                                                                         | ...........................................................................................58          |
| 6.4.3.                                                                                                    | Adverse events                                                                                                                                                                                           | .............................................................................................58        |
| 6.4.4. significant                                                                                        | Adverse event of special interest, serious adverse events and deaths, other events......................................................................................................60               |                                                                                                        |
| 6.4.5. Immunological 6.4.6.                                                                               | Laboratory findings........................................................................................67                                                                                            | events....................................................................................61           |
| 6.4.7.                                                                                                    | Post marketing experience                                                                                                                                                                                | .............................................................................68                        |
| 6.4.8.                                                                                                    | Safety related to drug-drug interactions and other interactions                                                                                                                                          | ...........................68                                                                          |
| 6.4.9.                                                                                                    | Overall discussion and conclusions on clinical safety                                                                                                                                                    | ..........................................68                                                           |
| 7. Risk management plan ........................................................................70        | 7. Risk management plan ........................................................................70                                                                                                       |                                                                                                        |
| 7.1.                                                                                                      | Safety specification                                                                                                                                                                                     | ..........................................................................................70           |
| 7.1.1. 7.1.2. Discussion                                                                                  | Proposed safety specification ..........................................................................70 on proposed safety specification                                                              | ......................................................70                                               |
|                                                                                                           | Pharmacovigilance plan                                                                                                                                                                                   |                                                                                                        |
| 7.2.                                                                                                      |                                                                                                                                                                                                          | ....................................................................................70                 |

<div style=\"page-break-after: always\"></div>

| 7.2.1.   | Proposed pharmacovigilance plan....................................................................70             |                                                                                                    |
|----------|-------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| 7.2.2.   | Discussion on the pharmacovigilance plan ........................................................70               |                                                                                                    |
| 7.3.     | Plans for post-authorisation efficacy studies                                                                     | ........................................................71                                         |
| 7.4.     | Risk minimisation measures ..............................................................................71       |                                                                                                    |
| 7.4.1.   | Proposed risk minimisation measures                                                                               | ..............................................................71                                   |
| 7.4.2.   | Discussion on the risk minimisation measures...................................................73                 |                                                                                                    |
| 7.5.     | RMP summary and RMP annexes overall conclusion..............................................73                    |                                                                                                    |
| 7.6.     | Overall conclusion on the Risk Management Plan .................................................73                |                                                                                                    |
| 8.       | Pharmacovigilance ..............................................................................74                | Pharmacovigilance ..............................................................................74 |
| 8.1.     | Pharmacovigilance system ................................................................................74       |                                                                                                    |
| 8.2.     | Periodic safety update reports submission requirements .......................................74                  |                                                                                                    |
| 9.       | Product information ............................................................................75                | Product information ............................................................................75 |
| 9.1.     | Summary of product characteristics (SmPC)........................................................75               |                                                                                                    |
| 9.1.1.   | SmPC section 4.1 justification.........................................................................75         |                                                                                                    |
| 9.1.2.   | SmPC section 5.1 justification.........................................................................75         |                                                                                                    |
| 9.2.     | User consultation .............................................................................................75 |                                                                                                    |
| 9.3.     | Additional monitoring .......................................................................................75   |                                                                                                    |
| 10.      | Biosimilarity assessment...................................................................76                     |                                                                                                    |
| 10.1.    | Comparability exercise and indications claimed                                                                    | ..................................................76                                               |
| 10.2.    | Results supporting biosimilarity........................................................................76        |                                                                                                    |
| 10.3.    | Uncertainties and limitations about biosimilarity.................................................78              |                                                                                                    |
| 10.4.    | Discussion on biosimilarity ..............................................................................78      |                                                                                                    |
| 10.5.    | Extrapolation of safety and efficacy ..................................................................78         |                                                                                                    |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADA        | Anti-drug antibodies                                              |
|------------|-------------------------------------------------------------------|
| AE         | Adverse event                                                     |
| ANC        | Absolute neutrophil count                                         |
| ANC AUC0-t | Above baseline levels of the subject's absolute neutrophil count  |
| ANC Cmax   | Maximum absolute neutrophil count                                 |
| ANC Tmax   | Time of maximum change from baseline of absolute neutrophil count |
| AUC0-t     | Area under the curve from time zero to t                          |
| BPI        | Brief Pain Inventory                                              |
| CHMP       | Committee for Medicinal Products for Human Use                    |
| CI         | Confidence interval                                               |
| CTCAE      | Common terminology criteria for adverse events                    |
| DP         | Drug Product                                                      |
| DS         | Drug Substance                                                    |
| DSN        | Duration of severe neutropenia                                    |
| ECG        | Electrocardiogram                                                 |
| ECOG       | Eastern Cooperative Oncology Group                                |
| ELISA      | Enzyme-linked immunosorbent assay                                 |
| EMA        | European Medicines Agency                                         |
| FN         | Febrile neutropenia                                               |
| GCSF       | Granulocyte colony-stimulating factor                             |
| GLM        | General linear model                                              |
| IB         | Inclusion Body                                                    |
| INN        | International non-proprietary name                                |
| ISR        | Injection site reaction                                           |
| ITT        | Intent-to-treat                                                   |
| mPEG       | Methoxypolyethylene glycol                                        |
| MYL-1401H  | Pegylated Granulocyte Colony Stimulating Factor                   |
| Nab        | Neutralizing antibodies                                           |
| NLT        | Not Less Than                                                     |
| NMT        | Not More Than                                                     |
| PD         | Pharmacodynamics                                                  |
| PEG        | Polyethylene glycol                                               |
| PFS        | Prefilled syringe                                                 |
| PK         | Pharmacokinetics                                                  |
| PP         | Per-protocol (population)                                         |
| PRAC       | Pharmacovigilance Risk Assessment Committee                       |
| RMP        | Risk management plan                                              |
| SC         | Subcutaneous                                                      |

<div style=\"page-break-after: always\"></div>

| SmPC   | Summary of product characteristics   |
|--------|--------------------------------------|
| TEAE   | Treatment-emergent adverse event     |

<div style=\"page-break-after: always\"></div>

## 1. Executive summary

On 19 June 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a marketing authorisation application for the medicinal product Vivlipeg (pegfilgrastim) intended for the treatment of neutropenia.

Vivlipeg will be available as a 6 mg solution for injection in pre-filled syringe. Vivlipeg is an immunostimulant, colony-stimulating factor (ATC code: L03AA13) which stimulates the development and differentiation of mature and functionally active neutrophils from precursor cells in the bone marrow.

Vivlipeg is a biosimilar medicinal product. It is highly similar to the reference product Neulasta (pegfilgrastim), which was authorised in the EU on 22 August 2002.

Data show that Vivlipeg has comparable quality, safety and efficacy to Neulasta (pegfilgrastim).

The main evidence of bioequivalence of Vivlipeg was based on one PK/PD study (MYL-1401H-1001).

The full indication for Vivlipeg is:

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Vivlipeg should be prescribed and supervised by a physician experienced in oncology and/or haematology.

Detailed recommendations for the use of this product are described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

This report summarises the scientific review leading to the opinion adopted by the Committee for Medicinal Products for Human Use (CHMP).

<div style=\"page-break-after: always\"></div>

## 2. Administrative/regulatory information and recommendations on the procedure

## 2.1. Scientific advice and protocol assistance

The applicant did not seek scientific advice from the CHMP.

## 2.2. Eligibility to the centralised procedure

The applicant Biosimilar Collaborations Ireland Limited submitted on 26 March 2025 an application for marketing authorisation to the European Medicines Agency (EMA) for Vivlipeg (pegfilgrastim), through the centralised procedure. This application was submitted in accordance with Article 82.1 of Regulation (EC) No 726/2004, as a multiple of Fulphila authorised on 20 November 2018.

The applicant applied for the following indication: Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

## 2.3. Legal basis, dossier content and multiples

## The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC, as amended - relating to applications for a biosimilar medicinal product.

The application submitted is composed of administrative information, complete quality data, appropriate non-clinical and clinical data for a similar biological medicinal product.

This application is submitted as a multiple of Fulphila authorised on 20 November 2018 in accordance with Article 82.1 of Regulation (EC) No 726/2004.

The chosen reference product is:

Medicinal product which is or has been authorised in accordance with European Union provisions in force for not less than 10 years in the EEA:

Medicinal product authorised in the European Union/Members State where the application is made for European reference medicinal product:

Medicinal product which is or has been authorised in accordance with European Union provisions in force and to which bioequivalence has been demonstrated by appropriate bioavailability studies:

| Product name, strength, pharmaceutical form:   | Neulasta, 6 mg, solution for injection   |
|------------------------------------------------|------------------------------------------|
| Marketing authorisation holder:                | Amgen Europe B.V.                        |
| Date of authorisation:                         | 22 August 2002                           |
| Marketing authorisation granted by:            | European Union                           |
| Marketing authorisation number:                | EU/1/02/227/001-002, 004                 |

## 2.4. Information on paediatrics

Not applicable

<div style=\"page-break-after: always\"></div>

## 2.5. Information on orphan market exclusivity

## 2.5.1. Similarity with authorised orphan medicinal products

Pursuant to Article 8 of Regulation (EC) No 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products from the start of the procedure because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 2.6. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:    | Janet Koenig     |
|----------------|------------------|
| Co-Rapporteur: | Alexandre Moreau |

| The application was received by the EMA on                                                                                                                                               | 26 March 2025   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| The procedure started on                                                                                                                                                                 | 21 April 2025   |
| The CHMP Rapporteur's first Assessment Report was received on                                                                                                                            | 28 May 2025     |
| The CHMP Co-Rapporteur's first Assessment Report was added to the Rapporteur's report on                                                                                                 | 28 May 2025     |
| The PRAC Rapporteur's first Assessment Report was added to the Rapporteurs' report and circulated to all PRAC and CHMP members on                                                        | 28 May 2025     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                 | 5 June 2025     |
| The Biologics Working Party agreed on the Assessment Overview during their meeting on                                                                                                    | 12 June 2025    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Vivlipeg on | 19 June 2025    |

## 2.7. Final CHMP outcome

## 2.7.1. Considerations related to orphan market exclusivity

The requirements of the submitted dossier in relation to orphan market exclusivity are described in section 2.6 of this report.

## 2.7.2. Final opinion

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Vivlipeg is favourable in the following indication:

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

<div style=\"page-break-after: always\"></div>

The CHMP, therefore, recommends the granting of the marketing authorisation subject to the conditions described in the following sections.

## 2.7.3. Conclusions on biosimilarity and benefit risk balance

Based on the review of the submitted data, Vivlipeg is considered biosimilar to Neulasta. Therefore, a benefit/risk balance comparable to the reference product can be concluded.

## 2.7.4. Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

## 2.7.5. Other conditions and requirements of the marketing authorisation

## 2.7.5.1. Periodic safety update reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7.6. Conditions or restrictions with regard to the safe and effective use of the medicinal product

## 2.7.6.1. Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## 2.7.7. Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

<div style=\"page-break-after: always\"></div>

## 3. Introduction

## 3.1. Therapeutic context

Vivlipeg (pegfilgrastim), a multiple of Fulphila (EMEA/H/C/004915) , was approved as a similar product to Neulasta (EU) which was granted a marketing authorisation on 22 of August 2022.

The proposed indication for Vivlipeg is the same as that approved for the reference product Neulasta, which is for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). The recommended dose is 6 mg administered as a subcutaneous (SC) injection approximately 24 hours after cytotoxic chemotherapy.

## 3.2. Aspects of development

The demonstration of biosimilarity was based on a physicochemical and biological characterisation. No new non-clinical or clinical studies were conducted.

## 3.3. Description of the product

Pegfilgrastim is a granulocyte colony-stimulating growth factor (G-CSF) shown to regulate the production and release of neutrophils from the bone marrow.

Vivlipeg has the same indication, pharmaceutical forms, strengths and presentations as approved for Fulphila.

## 3.4. Inspection issues

## 3.4.1. Good manufacturing practice (GMP) inspection(s)

No inspection required.

## 3.4.2. Good laboratory practice (GLP) inspection(s)

No inspection required.

## 3.4.3. Good clinical practice (GCP) inspection(s)

No inspection required.

<div style=\"page-break-after: always\"></div>

## 4. Quality aspects

## 4.1. Introduction

The finished product is presented as a solution for injection containing 6 mg pegfilgrastim (INN) as active substance.

Other ingredients are sodium acetate, D-sorbitol, polysorbate 20 and water for injections.

The product is available in a pre-filled syringe (Type I glass), with a fluorotec-coated bromobutyl plunger stopper and a stainless steel needle with or without an automatic needle guard.

Vivlipeg is a duplicate of Fulphila that has been developed as biosimilar medicinal product to the reference product Neulasta. According to the applicant, all documentation submitted in Module 3 are replicated from Fulphila's approved MAA.

The name Pegfilgrastim (MYL-1401H) is used to describe the active substance in this application.

## 4.2. Active substance

## 4.2.1. General information

Pegfilgrastim active substance (AS) is a conjugate of recombinant methionyl human granulocyte colony-stimulating factor (r-met-HuG-CSF; filgrastim), covalently linked to a 20 kDa monomethoxypolyethylene glycol (mPEG).

Vivlipeg (duplicate of Fulphila) is an E.coli -derived non-glycosylated rhG-CSF, consists of 175 amino acids and is identical to natural human G-CSF except for the presence of an additional methionine at the N-terminal end, which is covalently linked to a single 20 kDa PEG (overall relative molecular mass of approx. 40 kDa). Filgrastim has an  -helical structure and contains five cysteine residues, four of which form two intra-molecular disulphide bonds required to maintain the biologically active conformation of the protein.

## 4.2.2. Manufacture, characterisation, and process controls

The active substance is manufactured at two sites: at Biocon Biologics Limited, Electronics City, Bengaluru, India as well as at Biocon Biologics Limited, Bommasandra Post, Bengaluru, India.

## Description of manufacturing process and process controls

The Pegfilgrastim active substance manufacturing process has been adequately described.

The manufacturing process is a convergent process of the two critical intermediates recombinant filgrastim and activated mPEG.

The upstream process of GCSF manufacture is a high density E. coli cell culture process. The process ends with the harvest and cell lysis to gain the inclusion bodies (IB) containing the protein of interest. One batch of IBs (corresponding to the harvest of one upstream processing (USP) run) is further processed downstream by the purification process starting with thawing and solubilisation of the IBs followed by a refolding step and additional chromatographic and filtration purification steps. The intermediate is formulated and stored until PEGylation.

The manufacture and control of the activated mPEG has been adequately described.

<div style=\"page-break-after: always\"></div>

Batches of the intermediate GCSF are pooled for PEGylation. The PEGylated GCSF is purified by a series of chromatography and filtration steps, including bioburden reduction filtration into appropriate containers. A batch numbering system is in place and has been described.

No reprocessing is claimed for AS manufacture. The bulk AS is shipped from the AS manufacturing site to the finished product (FP) manufacturing site for processing to finished product. The process has been adequately defined and in-process controls (IPCs) described to control the process.

## Control of materials

G-CSF is expressed in an E.coli expression system.

The generation of the expression plasmid and the production strain has been described. A synthetic GCSF gene has been prepared in order to optimise the codon usage for expression in E.coli .

Characterisation data of the active substance show that the transcription of the synthetic gene results in the desired amino acid sequence. A standard two-tier cell banking system is used (master cell bankMCB and working cell bank-WCB) and cell banks and appropriate stability testing criteria are established for cell bank testing. The criteria applied for testing of the current WCB will be applied for future testing upon establishment of a new WCB.

Stability of the expression construct was investigated by generating and testing an end-of-production cell bank (EoPCB) and a post-production cell bank (PPCB).

Information on the raw materials is considered satisfactory. Compendial raw materials are tested in accordance with the corresponding monograph. If no compendial monograph is available, in-house specifications have been set.

Some column resins/filters contain specified materials of animal origin. Respective TSE certificates have been provided.

The synthesis of mPEG aldehyde is adequately described. The PEGylation reagent, activated mPEG has been classified as an intermediate.

## Control of critical steps and intermediates

The manufacturing process employs multiple controls to ensure consistent quality of the active substance. Critical process steps have been defined during development and process characterisation. Before initiation of the process characterisation experiments, a Failure Mode and Effect analysis (FMEA) risk assessment was conducted to identify which process parameters could have an impact on product quality. These parameters are termed potential critical process parameters (pCPP). Process characterisation experiments were performed to identify real CPPs from the list of pCPPs.

The manufacturing process description is very detailed. Critical and non-critical process parameters (PPs) are defined with their acceptable ranges. The classification of the PPs is considered conclusive and consistent.

In-process controls (IPC) and in-process tests (IPT) have been defined to ensure consistent quality of the active substance. Acceptance criteria, and relative ranges, have been adequately justified.

Overall, together with the non-critical PPs and the proposed IPCs and IPTs, the upstream process is considered adequately controlled. The composition of the media, feed solutions and buffers are stated. The downstream process is considered adequately described and controlled by the proposed in process controls and tests.

<div style=\"page-break-after: always\"></div>

G-CSF is considered a critical intermediate. Appropriate tests for identity, purity, content and potency are included. Batch analysis and stability data of G-CSF are acceptable. The proposed storage condition and time for this intermediate in specified containers is accepted.

The activated PEG is declared as being manufactured under GMP conditions in compliance with ICH Q7. The QP declaration certificate confirming the GMP status is in order. The starting material has been defined. The manufacturing process has been elaborated in sufficient detail. All relevant information on mPEG-AL and the starting material is provided.

Release and stability specifications are provided.

## Process validation

The pegfilgrastim active substance manufacturing process has been validated adequately. Consistency in production has been shown on an appropriate number of commercial batches. Appropriate protocols for the validation of i) the manufacture of the intermediate G-CSF and ii) PEGylation of G-CSF were provided. All acceptance criteria for the critical operational parameters and likewise acceptance criteria for the in-process tests are fulfilled demonstrating that the purification process consistently produces active substance of reproducible quality that complies with the predetermined specification and inprocess acceptance criteria. Hold periods for process intermediates have been qualified by data on physicochemical stability and bioburden for in-process stages and buffer solutions.

The clearance of process-related impurities (host cell proteins, DNA and other specified impurities) has been satisfactorily evaluated and supports the proposed control strategy. Chromatography resin and ultrafiltration cartridge lifetimes have been appropriately qualified. Validation also includes details of process plant cleaning validation, leachables and extractables evaluation for process plant contact materials and finished active substance shipping validation.

Column re-use is foreseen during the manufacture of G-CSF and the number of cycles is defined based on respective re-use validation studies included in the dossier which are considered acceptable. Specified membrane re-use is also suitably discussed.

## Manufacturing process development

The manufacturing process development of pegfilgrastim active substance was initially based on a manufacturing process which was then optimised to the commercial process.

A comparability study has been carried on pre- and post-change batches, and data provided demonstrated that the change did not have a significant influence on the quality of the product.

Comprehensive process characterisation (PC) studies have been performed for the single process steps and based on the results the process parameters were classified with respect to their criticality. The scaled-down models used for these studies were representative of the at scale manufacturing process.

## Characterisation

The active substance has been comprehensively characterised by orthogonal methods.

The applicant has provided characterisation data on both pegfilgrastim and the protein backbone alone, G-CSF.

The intact molecular mass of the entire molecule was confirmed. The correct attachment of PEG to the primary PEGylation site was verified. The mass was within the expected range, substantiating the correct attachment of the PEG moiety. The disulphide bond structure of pegfilgrastim was shown to be consistent with the expected structure. Overall, the primary sequence of pegylated G-CSF was confirmed.

<div style=\"page-break-after: always\"></div>

The apparent molecular weight was also analysed. The secondary and tertiary structure of pegfilgrastim was analysed. The size variants were analysed by various methods. Surface plasmon resonance (SPR) was used to determine the binding kinetics to the G-CSF receptor. The results were comparable within the batches of pegfilgrastim and to the reference product. The biological activity of pegfilgrastim was investigated using the compendial NFS-60 cell proliferation assay. The results were within the predefined acceptance criteria and confirm that pegfilgrastim possesses the correct threedimensional structure and exhibits qualitatively and quantitatively the expected biological activity.

The G-CSF (before the PEGylation step) was characterised with respect to intact mass, primary structure, confirmation of the disulphide bonds, higher order structure, and biological activity. Qualification data for the potency assay were provided substantiating its suitability. Overall, the identity and the expected structure of the G-CSF could be confirmed.

The PEG moiety was characterised. These data confirm the expected molecular mass and distribution.

Orthogonal chromatographic methods were applied to analyse purity and impurities. Characterisation of the impurities was performed thoroughly with respect to identification of the impurities and their stability indicating properties. Size-related variants were identified. The main degradation pathways of Pegfilgrastim are dimerisation/ oligomerisation, truncation and Des-PEGylation and oxidation, as confirmed by stress studies. Overall, the characterisation of product-related impurities is considered comprehensive, and the results are consistent across the orthogonal methods.

Process-related impurities were monitored during manufacture of the consistency batches. The small molecule impurities were consistently below the detection level. Data for HCP and DNA were below the detection levels. Free PEG was detectable at consistently low levels in the more concentrated AS solution. Bacterial endotoxin was below detection level in the finished AS.

The potential for nitrosamine impurities arising from the DS and DP manufacturing processes at Site-1 and Site-2 was assessed in accordance with global regulatory guidelines considering all potential sources of nitrosamine contamination. Based on the risk assessment, no sources were identified that could cause nitrosamine impurities in either DS or DP

In summary, the characterisation is considered appropriate for this type of molecule.

## 4.2.3. Specification

## Specifications

The active substance specification includes test parameters on identity, potency and content, purity, impurities, excipients, microbiological safety. The list of parameters is considered comprehensive. The active substance release and shelf-life specifications are identical overall (and contain the same number of parameters) but differ in the acceptance limits for AS-related impurities.

Biological activity (potency) of the active substance is determined by parallel line assay using M-NFS60 cells. The cells depend on the presence of growth factors like G-CSF for their viability and proliferation. The potency assay mimics the functioning of Pegfilgrastim (MYL-1401H) based on the purported mechanism of action in vivo . There is a defined concentration range of G-CSF in which a linear correlation between the proliferation of the cells when stimulated with growth factor is observed. Determination of proliferation is carried out by photometric measurement of absorption observed from the reduction of tetrazolium compound (formazan) which produces colour under assay conditions.

The release specification limits for post peaks by RP-HPLC and HMWP by SE-HPLC were established in consideration of the proposed shelf-life limits and the rate of degradation observed for these species over the proposed shelf life.

<div style=\"page-break-after: always\"></div>

## Analytical procedures and reference standards

The descriptions of non-compendial analytical methods used in the control of the active substance have been provided and are found to be acceptable in the level of detail.

Residual DNA is an in-house method using commercial extraction and quantitative kits. Residual HCP is determined by a commercial ELISA kit. Overall, sufficiently detailed information has been provided with regard to the validation of the proposed in-house analytical procedures. The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with ICH guidelines.

## Batch analysis

Batch release results have been provided for AS batches, that were included in clinical studies, process validation and stability studies. All batches comply with the predefined specification acceptance criteria in place at the time of analysis.

Batch release results have been provided for several batches of AS, that were included in clinical studies, process validation and stability studies. The batches were produced at commercial scale. All batches comply with the predefined specification acceptance criteria in place at the time of analysis. In addition, batch data provided represent the early and final commercial processes.

## Reference materials

Sufficient details have been provided on the reference standard system established for AS manufacture. In-house laboratory standards (internal reference standards, IRS) and certified reference materials are used. The currently used primary IRS used for PEG-GCSF potency measurement has been adequately qualified. Any secondary IRS will be qualified against the primary IRS in terms of potency which is considered adequate.

## Container closure

Formulated AS solution is stored in depyrogenated, clear, Ph. Eur. compliant Type I glass bottles. The bottles are closed using a polypropylene screw cap with pouring ring made of polypropylene.

## 4.2.4. Stability

A suitable 24-month shelf life is determined for active substance when stored at 2-8C in Type I glass bottles.

Stability data are provided for several commercial AS batches which have been stored for the proposed shelf-life at the proposed long-term storage condition and for a specified period at accelerated conditions which is in accordance with ICH requirements. The stability protocols comprise all AS release test parameters and are therefore considered appropriate. Stability-indicating methods have been used in investigations. The data provided show that the batches complied with limits in force at that time although the specifications have been updated during the study but also with the proposed AS specification containing tighter limits for the product-related substances.

## 4.3. Finished medicinal product

## 4.3.1. Description of the product and pharmaceutical development

Vivlipeg finished product (FP) consists of MYL-1401H pegfilgrastim as active substance, D-sorbitol (tonicity agent), polysorbate 20 (stabilising agent) and sodium acetate buffer (buffering agent).

<div style=\"page-break-after: always\"></div>

Vivlipeg is supplied in a single-use prefilled syringe (PFS) containing 0.6 mL of the solution at a protein concentration of 10 mg/mL resulting in 6 mg pegfilgrastim active substance per syringe. A specified overfill is included to ensure a withdrawal of 0.60 mL. The qualitative composition of Vivlipeg is the same as that of the reference product Neulasta. All excipients comply with the specifications described in the respective Ph. Eur. monographs. It has been confirmed that the excipients used during the production of the medicinal product are not of animal origin and all excipients are well known and widely used in pharmaceutical products. The intended commercial formulation is the same as that used in clinical trials.

Despite identical target concentrations with the reference product, various studies were performed during pharmaceutical development to further support the proposed final composition of Vivlipeg. Taking all study results together the qualitative and quantitative composition of Vivlipeg is sufficiently justified with regard to finished product stability.

Adequate characterisation studies were performed on the FP manufacturing process. The acceptable ranges of the process parameters were appropriately evaluated with regard to product quality and stability. Compatibility of all materials of construct used for FP manufacture and product stability was confirmed. A maximum filter contact period with regard to FP quality was established, too, by adequate filter compatibility studies.

The finished product is filled into a Ph. Eur. Type I glass PFS closed with a bromobutyl elastomer with a Fluorotec   coating and fitted with a staked hypodermic needle. The PFS is presented with or without a needle guard. Appropriate compatibility studies were also conducted with Vivlipeg formulation and the selected primary packaging system including a thorough evaluation of extractables and leachables. The suitability of the selected container closure system and its compatibility with Vivlipeg FP is satisfactorily demonstrated. Container closure integrity test used during stability studies to replace sterility testing and during manufacturing process validation was appropriately validated.

A risk assessment on elemental impurities in Vivlipeg FP was conducted in line with ICH Q3D. Subsequent analysis of DP lots confirmed the absence of metal residues.

## 4.3.2. Manufacture of the product and process controls

All manufacturing and testing sites are covered by valid GMP certificates.

Representative batch formulas are presented for the three validated batch scales.  The batch numbering system is satisfactorily explained.

The manufacturing process is depicted in detail. The entire manufacturing process is separated in three stages. Stage A includes all steps up to the final formulated DP. Stage B comprises sterile filtration and filling. In stage C the filled syringes are visual inspected and then assembled with the plunger rod and a needle guard. In addition, the single process steps are additionally described along with the inprocess controls (IPC)/tests (IPT) performed at this stage.

The process description is satisfactory. The final formulated bulk is controlled for bioburden and subsequently sterile filtered. All sterilising filters are tested for integrity pre- and post-use.

All process parameters applied during manufacture are listed together with their target value and the proven acceptable ranges (PAR) as evaluated during pharmaceutical development or process validation. The applicant's designation to critical and non-critical process parameters is acceptable.

The maximum hold times are supported by appropriate data generated in hold time studies.

<div style=\"page-break-after: always\"></div>

Manufacturing process validation was performed by the manufacture of an adequate number of consecutive DP batches for each of the three batch sizes. The process parameters applied during the manufacture were kept within their PARs. Overall, the process validation programs applied were adequate to evaluate process consistency. All parameters checked during manufacture or at release were within the pre-defined ranges and all results of the IPCs met the predefined acceptance criteria. The batch release results complied with the DP specification acceptance criteria. Hence, the DP manufacturing process can be considered validated for all three batch sizes.

Validation of the aseptic conditions during filling was demonstrated by media fill runs. The impact of shipping on Vivlipeg stability was adequately studied by various storage and shipping studies conducted with AS and FP samples. Evidence was provided that the routine conditions during shipment can maintain the desired temperature range.

Finally, it was demonstrated that the technical properties of the PFS and the product quality characteristics are not negatively affected by the assembly process of the PFS with the needle guard.

The container closure components are purchased pre-sterilised.

## 4.3.3. Product specification

The FP specification includes test parameters on identity, potency and content, purity and impurities, pharmaceutical properties, microbiological safety, pre-filled syringe functionality and safety device testing. Various methods are applied for purity and impurities analysis as RP-HPLC, SEC and CIEX. All acceptance limits are adequately justified.

In-house analytical methods used in the control of finished product are common with those of the active substance with the exception of product-specific parameters. Methods are appropriately validated in accordance with ICH guidelines. The analytical methods are shown to be stability indicating. The protocols and the reports on method transfer of the potency assay used at the sites responsible for QC testing on importation into the EU has been provided.

Batch release results of several DP batches, manufactured at the validated commercial scales and used in clinical studies/process validation/stability studies are presented. All results comply with the specification acceptance criteria applicable at the time of testing and confirm consistency of the manufacturing process. In addition, analysis of DP batches in comparison to Neulasta batches did not reveal any new unknown impurities.

The FP is released against the same reference standards and control materials described for the DS.

Acceptable specifications are provided for all parts of the PFS, and the specification limits are adequately justified. According to the Certificates of Analysis provided, all parts in contact with the finished product comply with the respective pharmacopeial monographs. The suppliers of all primary packaging components are indicated as well as the sterilisation methods and the sterilisation sites.

The secondary packaging components consist of the blister pack, printed carton and labelling.

## 4.3.4. Stability of the product

The proposed FP shelf-life in the commercial container system is 36 months when stored at 53C.

Stability studies have been initiated in accordance with ICH requirements with Vivlipeg DP batches at commercial scale. Stability-indicating methods have been used in investigations. Stability data at recommended storage temperature have been presented for a suitable number of DP lots packaged in the proposed container closure system, as well as for process validation batches. Here, not only physicochemical parameters but also functional stability has been tested. No out-of-specification

<div style=\"page-break-after: always\"></div>

results have been reported. Under accelerated conditions, an increase in some of the impurities could be observed in the DP.

The parameters 'extractable volume' and 'actuation of safety device' were checked in a separate functional stability study. The results obtained so far do not show any impact on extractable volume and actuation of the safety device of the PFS.

Forced degradation studies were performed in the course of analytical comparability evaluation against Neulasta. These data confirm that Vivlipeg DP is susceptible to degradation when subject to several stress agents (e.g. photo exposure, mechanical stress, acidic and alkaline pH).

For long-term storage, appropriate instructions are included in the SmPC section 6.4 ('store in a refrigerator (2C-8C))'. Moreover, the warning to keep the container in the outer carton is supported by the results of the photo-stability study. The SmPC storage instruction that Vivlipeg may be exposed to not more than 30C for a maximum of 72 hours is supported by stability data.

Vivlipeg PFS stability after freezing has been demonstrated with the applicants own data. However, in view of a potential impact on container closure integrity freezing of the PFS is not recommended.

In conclusion, appropriate stability studies on Vivlipeg DP have been conducted. The claimed DP shelf life of 36 months when stored at 2-8C is supported by sufficient data and acceptable.

## 4.3.5. Comparability exercise for finished medicinal finished product

The primary sequence has been confirmed as has the site of PEGylation. Secondary and higher order structures were investigated by various orthogonal analytical methods. Overall, it can be concluded that the biosimilar MYL-1401H is highly similar to the reference product in terms of primary, secondary and tertiary structure. This was further confirmed by the data showing similarity with respect to potency.

Purity and impurities were investigated. High and Low-molecular -weight species were analysed. Comparability of biosimilar and reference product in terms of stability has been investigated and no particular issues regarding the stability of MYL-1401H arose during DS and DP stability studies.

The similarity of EU to US-Neulasta is considered sufficiently demonstrated. This is of importance since several clinical studies were performed using the US-derived reference product. A summary of the biosimilarity studies is shown in table below:

<div style=\"page-break-after: always\"></div>

Table 1: Summary of biosimilarity studies

| Molecular parameter   | Attribute           | Methods for control and characterization                     | Key findings                                    |
|-----------------------|---------------------|--------------------------------------------------------------|-------------------------------------------------|
| Primary structure     | Amino acid sequence | Peptide mass fingerprinting (Glu-C digest)                   | Identical primary sequence to reference product |
| Primary structure     | Amino acid sequence | Peptide mass fingerprinting (Trypsin digest)                 | Identical primary sequence to reference product |
| Primary structure     | Amino acid sequence | Intact MALDI TOF MS                                          | Highly similar.to reference product             |
| Primary structure     | Reavlation site     | N-terminal Peaylation by GluC digestion - MALDI- TOF MS      | Highly similar.to reference product             |
| Primary structure     | Reavlation site     | N-terminal Reavlation by CMBr/trypsin digestion - ESI-TOF MS | Highly similar.to reference product             |
| Primary structure     | Reavlation site     | N-terminal Reavlation by Trypsin digestion - MALDI-TOF MS    | Highly similar.to reference product             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                        | Polydispersity                   | MALDI-TOF                                                      | Highly similar to reference product                                                                     |
|------------------------|----------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| Higher order structure | Secondary and tertiary structure | Non-reduced peptide mass fingerprint Glu-C Digest (disulphide) | Identical to reference product                                                                          |
|                        |                                  | Far UV CD spectroscopy                                         | Highly similar to reference product                                                                     |
|                        |                                  | FTIR.                                                          | Highly similar to reference product                                                                     |
|                        |                                  | Ellman's reagent (free Cysteine)                               | Highly similar to reference product                                                                     |
|                        |                                  | Extrinsic Fluorescence                                         | Highly similar to reference product                                                                     |
|                        |                                  | Near UV CD spectroscopy                                        | Highly similar to reference product                                                                     |
|                        |                                  | Differential scanning calorimetry                              | Highly similar to reference product                                                                     |
|                        |                                  | Intrinsic Fluorescence                                         | Highly similar to reference product                                                                     |
|                        |                                  | 1D NMR                                                         | Highly similar to reference pnpoid                                                                      |
| Biological Activity    | Potency                          | MNFS-60 cell proliferation                                     | Highly similar to reference product                                                                     |
|                        | Receptor Binding                 | Surface Plasmon Resonance                                      | Highly similar to reference pnpoid                                                                      |
| Charge                 | Isoelectric point                | cIEF                                                           | Highly similar to reference product                                                                     |
| Purity/Impurities      | HMWP-1 (Aggregates)              | SEC-UV AUC SEC-MALS                                            | Marginally higher than reference pnpoid Highly similar to reference product Highly similar to reference |
|                        | Di-PEG-G-CSF                     | SEC-UV                                                         | Lower than reference product                                                                            |
|                        |                                  | CIEX                                                           | Lower than reference product                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Molecular parameter         | Attribute                   | Methods for control and characterization   | Key findings                                                                                                        |
|-----------------------------|-----------------------------|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
|                             | Dimer                       | SEC-UV RP-HPLC                             | Lower than reference product Lower than reference product                                                           |
|                             | Des-PEG-G-CSF               | RP-HPLC SEC-UV                             | Marginally higher than reference pnpoid Highly similar to reference product                                         |
|                             | M138 0xidation              | RP-HPLC                                    | Highly similar to reference product                                                                                 |
|                             | Q108 Deamidation            | RP-HPLC                                    | Marginally higher than reference product                                                                            |
|                             | Total hydrophobic pre-peak  | RP-HPLC                                    | Highly similar to reference product                                                                                 |
|                             | Total hydrophobic post-peak | RP-HPLC                                    | Marginally higher than reference pnpo.id                                                                            |
|                             | Purity by                   | RP-HPLC CIEX SEC-UV                        | Highly similar to reference pnpoud Marginally higher than reference product Marginally higher than reference pnpoid |
| Finished product attributes | Composition                 |                                            | Identical to reference product                                                                                      |
|                             | Protein content             | UV280                                      | Highly similar to reference pnpoid                                                                                  |
|                             | Subvisible particles        | Micro-flow imaging                         | Lower than reference product                                                                                        |

## 4.3.6. Post approval change management protocol(s)

A PACMP is provided about scale up of downstream process of Pegfilgrastim AS manufacturing at site-2 facility, located within the EMA approved manufacturing facility of Biocon Biologics Limited, Bengaluru, India.

To augment the active substance manufacturing capacity to increase the batch size, it is proposed to increase the downstream scale and start the downstream process with higher amount of IB's.

The protocol outlines the overall approach for management of this change. The proposed PACMP is considered accepted.

A protocol for post-approval establishment of master cell bank (MCB) and working cell bank (WCB) is provided that is, overall, considered acceptable.

<div style=\"page-break-after: always\"></div>

The applicant included a PACMP covering the addition of a testing site for finished product release to ensure uninterrupted EU importation testing. No changes are being made to the analytical methods. The only change being made is to the location of the testing laboratory. The additional laboratory is in the process of being GMP-approved. No release testing will occur from additional batch control testing site until approval of the laboratory is provided. The new site will be qualified according to an analytical method transfer protocol. The data from the analytical method transfer will be submitted as a Type IB variation. The proposed PACMP is deemed acceptable.

## 4.3.7. Adventitious agents

Contract vendors are stated as having been audited and only animal origin-free materials procured for cell banking and manufacture of bulk AS. Raw materials are confirmed free of Transmissible Spongiform Encephalopathies and Bovine Spongiform Encephalopathies and in compliance with the Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01). All have been confirmed as being of yeast or vegetable origin.

TSE certificates provided for materials of biological and non-biological origin used throughout active substance and finished product manufacture have been provided

The control of microbial contamination has been evaluated elsewhere in the dossier.

Viral adventitious agents are not applicable for the E.coli cell line. Cell banks have been satisfactorily evaluated for presence of bacteriophage.

## 4.3.8. Medical Device

Fulphila (original MAA) received marketing authorisation in 2018, prior to the implementation of the updated requirements introduced under Article 117 of Directive 2001/83/EC, as amended by Regulation (EU) 2017/745 on Medical Devices (MDR), which became applicable on 26 May 2021.

The safety and functional performance of the device have been assessed and verified as part of the original marketing authorisation application for Fulphila. In the context of this duplicate application, the applicant confirms the following:

1. No Changes to the Device
2. This is a Duplicate MAA Submission of authorised Fulphila
3. Device Safety and Functional Performance identical to Approved Fulphila.

## 4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects

Based on the review of the quality data provided, the CHMP considers that the marketing authorisation application for Vivlipeg is approvable from the quality point of view.

The development, characterisation, manufacture and control of Vivlipeg active substance and finished product are adequately described. Vivlipeg is a duplicate of Fulphila, for which, analytical similarity of Fulphila finished product to the reference product Neulasta (EU) has been satisfactorily demonstrated. Likewise, the analytical similarity of Neulasta sourced from EU and US was proven.

Overall, the quality of Vivlipeg finished product is considered to be acceptable when used in accordance with the conditions defined in the SmPC.

<div style=\"page-break-after: always\"></div>

## 5. Non-clinical aspects

## 5.1. Introduction

The non-clinical data in support of Vivlipeg are identical to the non-clinical data of the Fulphila dossier, which have been assessed and authorised by the CHMP. No new non-clinical data have been submitted.

## 5.2. Analytical methods

## N/A

## 5.3. Pharmacology

No in vitro or in vivo pharmacodynamics animal studies investigating analytical, physiochemical and functional similarity between Vivlipeg and Fulphila/Neulasta were conducted in addition to the analytical biosimilarity assessment.

## 5.3.1. Pharmacokinetics

Neither stand-alone comparative pharmacokinetics studies nor separate absorption, distribution, metabolism and/or excretion studies with Vivlipeg and Fulphila/Neulasta were performed by the applicant.

## 5.4. Toxicology

No non-clinical studies with Vivlipeg were performed by the applicant.

## 5.4.1. Ecotoxicity/environmental risk assessment

According to the Guideline on the environmental risk assessment of medicinal products for human use - First version (EMEA/CHMP/SWP/4447/00 Rev. 1- Corr.*), in the case of products containing proteins as active pharmaceutical ingredient(s), an environmental risk assessment (ERA) should be provided, whereby this ERA consists of a justification for not submitting ERA studies, e.g. that due to the nature of particular pharmaceuticals they are unlikely to result in a significant risk to the environment. In line with this, the applicant provided a valid justification for the absence of ERA studies with Vivlipeg, which is deemed acceptable.

It is considered that Vivlipeg will not pose any greater risk to the environment than Fulphila/Neulasta. Pegfilgrastim is extensively metabolised in man and predicted to be rapidly biodegraded in the environment. Furthermore, it is considered that Vivlipeg will replace other similar pegfilgrastim products on the market. Hence, it is expected that the total amount of pegfilgrastim will not be substantially increased and no additional environmental burden is envisaged. Furthermore, proteins and peptides are excluded from the need for an environmental risk assessment in accordance with the respective guideline.

<div style=\"page-break-after: always\"></div>

## 5.5. Overall discussion and conclusions on non-clinical aspects

## 5.5.1. Discussion

## Pharmacology

Vivlipeg (pegfilgrastim) is a covalent conjugate consisting of a recombinant human G-CSF polypeptide (175-amino acid residues; C845H1339N223O243S9) with a methoxy-polyethylene glycol (m-PEG) moiety attached at the N-terminal position. The reference medicinal product of Vivlipeg is Neulasta. The proposed indication for Vivlipeg is as the reference products for the Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

In vitro pharmacodynamic (PD) experiments comparing Vivlipeg activities and modes of action of different sources for the similarity exercise have been assessed in the quality part.

No in vivo pharmacodynamics animal studies investigating analytical, physiochemical and functional similarity between Vivlipeg and its referenced medicinal product Neulasta were conducted in addition to the analytical biosimilarity assessment.

This is accepted and in agreement with the EMA Guideline on similar biological medicinal products (CHMP/437/04 Rev 1; 2014) and the EMA Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev 1). In vitro assays may be considered paramount for the nonclinical biosimilar comparability exercise since they are generally more specific and sensitive in detecting differences between the biosimilar and the reference product.

For review of the biosimilar comparability exercise, please refer to the discussion and conclusions on the quality section.

## Pharmacokinetics

Neither stand-alone comparative pharmacokinetics studies nor separate absorption, distribution, metabolism and/or excretion studies were performed with Vivlipeg and Fulphila/Neulasta.

As stated in the 'Guideline on similar biological medicinal products containing monoclonal antibodies nonclinical and clinical issues' [EMA/ CHMP/ BMWP/ 403543/ 2010]: If the comparability exercise in the in vitro studies is considered satisfactory and no factors of concern are identified, or these factors of concern do not block direct entrance into humans, an in vivo animal study may not be considered necessary.

Given the biosimilar comparability exercise between Vivlipeg and Neulasta and/or Fulphila on the analytical level, no further pharmacokinetic studies are deemed necessary.

## Toxicology

Generally, studies regarding toxicology, including developmental and reproductive toxicity studies, are not required for non-clinical testing of biosimilars according to the EMEA/CHMP/BMWP/42832/2005 Rev1 guideline. Neither are studies regarding safety pharmacology, carcinogenicity and local tolerance.

## Environmental risk assessment

The active substance is a natural substance, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, Vivlipeg is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 5.5.2. Conclusions

The non-clinical aspects of pharmacology, pharmacokinetic and toxicology for Vivlipeg have been well characterised and are considered acceptable. There were no changes to the SmPC and the product information is aligned with Fulphila and the reference product Neulasta.

<div style=\"page-break-after: always\"></div>

## 6. Clinical aspects

## 6.1. Introduction

The clinical data in support of Vivlipeg are identical to the clinical data of the Fulphila dossier, which have been assessed and authorised by the CHMP. No new clinical data have been submitted.

## 6.1.1. GCP aspects

The clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 6.1.2. Tabular overview of clinical trials

Table 2: Tabular overview of main clinical studies

| Type of Study                      | Study Number   | Study Objective(s)                                                                                                                                                                         | Study Design                                                                                                                | Test Product(s), Dosage, Regimen, Route of Administration                               | Number of Subjects/ Diagnosis                                                                                                         | Duration of Treatment                                                                                 |
|------------------------------------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| PK/PD, safety                      | MYL-1401H-1001 | To compare the PK, PD, safety, and tolerability of MYL-1401H and NEULASTA                                                                                                                  | Single-centre, randomised, double- blind, 3-period, 3-treatment, 3-way crossover study                                      | MYL-1401H or NEULASTA (EU- approved NEULASTA or US-licensed NEULASTA) 2-mg SC injection | 216 healthy adult subjects                                                                                                            | Single dose                                                                                           |
| Immuno- genicity, safety           | MYL-1401H-1002 | To descriptively compare immunogenicity between 2 SC injections of MYL-1401H and NEULASTA To evaluate the safety and tolerability of MYL-1401H and NEULASTA after 2 injections (6 mg each) | Single-centre, randomised, open- label, 2-dose, parallel study                                                              | MYL-1401H or NEULASTA (US-licensed NEULASTA) 6-mg SC injection                          | 50 healthy adult subjects                                                                                                             | 2 doses                                                                                               |
| Efficacy, safety, immuno- genicity | MYL-1401H-3001 | To compare the efficacy, safety, and immunogenicity of MYL-1401H and NEULASTA                                                                                                              | Multicentre, randomised, double- blind, therapeutic- equivalence study Subjects were randomly assigned (2:1) to either MYL- | MYL-1401H or EU- approved NEULASTA 6-mg SC injection                                    | 194 adult patients with Stage II/III invasive breast cancer in the adjuvant/neo- adjuvant setting who were receiving TAC chemotherapy | Single dose of MYL-1401H or EU- approved NEULASTA on Day 2 of each chemotherapy cycle. Each cycle was |

<div style=\"page-break-after: always\"></div>

| 1401H or EU-NEULASTA and were stratified based on their age and country.   | approximately 3 weeks (from the first day of chemotherapy [Day 1 Cycle 1] to the last scheduled assessment in Cycle 1). Study treatment duration was up to 6 cycles of chemotherapy.   |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Abbreviations: EU = European Union; PD = pharmacodynamics; PK = pharmacokinetics; SC = subcutaneous; TAC = docetaxel, doxorubicin, and cyclophosphamide; US = United States.

## 6.2. Clinical pharmacology

## 6.2.1. Methods

ELISA Assay for the Quantitation of Fulphila (also referred as MYL-1401H) and Neulasta in Human Serum (has been satisfactorily validated and considered suitable for its intended use).

Neutrophils and CD34+ cells were counted via flow cytometry (Validation reports have not been submitted. Flow cytometry is considered a standard approach so that validation of this method is not needed for this application).

Analysis of Normal Human Serum Samples for detection of Anti-Drug Antibodies against MYL- 1401H and Neulasta (EU and US) to support Phase 1 Clinical Study (MYL-1401H-1001) using the Mesoscale Discovery Platform.

Cell-Based Assay to Detect Neutralizing Antibodies (NAb) Against MYL-1401H and Neulasta (EU and US) in Normal Human Serum.

## 6.2.2. Pharmacokinetics

## 6.2.2.1. Introduction

The pivotal cross-over PK/PD study MYL-1401H-1001 investigated single 2 mg doses of MYL-1401H, EU- and US-Neulasta (0.2 mL of 10 mg/mL dose strengths based on protein content with all 3 drug products being transferred into identical 0.3-mL syringes), whereas the parallel-design study 1002 used single 6 mg doses and primarily investigated immunogenicity in healthy subjects.

Also, in trial MYL-1401H-1002 concentrations of the analyte PEG GCSF were determined but analysed only descriptively (for the means of the primary objective of this trial immunogenicity).

Thus, trial MYL-1401H-1001 is the pivotal bioequivalence (and equivalent PD) study of this application.

<div style=\"page-break-after: always\"></div>

## 6.2.2.2. Bioequivalence

Trial MYL-1401H-1001 was a single centre, randomised, double-blind, 3-period, 3 treatments, 3-way crossover trial to evaluate the PD, PK, safety and tolerability of pegfilgrastim from a test product (MYL1401H) compared to reference products EU- and US-Neulasta in 216 healthy volunteers intended to be in accordance with EU and US biosimilar guidelines.

After randomisation to one of six possible treatment sequences, subjects were administered MYL1401H or one of two reference products in Period 1. After the 1 st  crossover, subjects received one of the remaining alternate treatments in Period 2.

After the 2 nd  crossover, subjects received the other alternate treatment in Period 3. The washout between drug administrations was at least 4 weeks.

<!-- image -->

2mgsubcutaneous(s.c)administration

Figure 1: Overview of study design MYL-1401H-1001

The inclusion and exclusion criteria can be briefly summarised as selecting for healthy adults (18-65 years of age) of both genders. Specific for the scope of the trial are only the two exclusion criteria:

- Known history of previous exposure to filgrastim, pegfilgrastim, GCSF or any analogue of these.
- Hypersensitivity to the constituents of Neulasta (sorbitol E420, polysorbate 20 and acetate or acetic acid) or hypersensitivity to E. coli derived proteins.

## Pharmacokinetic Measurements

At the time points defined blood samples of 2.5 mL each were taken for the analysis of PEG-GCSF concentration in serum samples.

## Pharmacodynamic Measurements

At the time points defined, blood samples of 3 mL each were taken for the analysis of ANC and CD34+.

Both ANC and CD34+ cell count was determined with flow cytometry by the clinical safety laboratory of the centre.

## Safety and Tolerability Measurements

Safety and tolerability assessments consisted of AEs, clinical laboratory, vital signs, 12-lead ECG, local tolerability, physical examination and immunogenicity and were performed as scheduled.

<div style=\"page-break-after: always\"></div>

## Primary PK Parameters

The primary PK parameters to be determined or calculated from the serum-concentration time data for PEG-GCSF were:

- Cmax = Observed maximum serum concentration
- AUC0-inf = Area under the serum concentration-time curve (time 0 to infinity)

Bioequivalence was to be concluded if the 90% CI for the ratio of geometric means of two treatments falls completely within the limits of 0.8000-1.2500 for the primary PK parameters.

## Secondary PK Parameters

The secondary PK parameters to be determined or calculated from the serum-concentration time data for PEG-GCSF were:

- AUC0-t = Area under the concentration-time curve (time 0 to time of last quantifiable concentration)
- Tmax = Time to attain maximum serum concentration
- kel = Terminal elimination rate constant
- t1/2 = Apparent terminal elimination half-life
- Vd/F = Apparent volume of distribution

An additional PK parameter to be determined or calculated from the serum-concentration time data for PEG-GCSF was:

- %AUCextra = Percentage of estimated part for the calculation of AUC0-inf of serum PEG-GCSF: ([AUC0-inf - AUC0-t]/AUC0-inf)*100%.

The chosen PK parameters are standard parameters for BE trials and accepted for demonstration of similar PK profiles of two pegfilgrastims.

## Primary PD Parameters

The primary PD parameters to be determined or calculated from the cell count-time data for ANC were:

- ANC AUC0-t = Area under the ANC above baseline values versus time curve (time 0 to time of last data collection point)

- ANC Cmax = Maximum change from baseline for ANC*

* ANC Cmax was changed from secondary PD parameter to primary PD parameter after completion of the study, as documented in CSP Version 3.0.

Equivalence was to be concluded if the 95% CI for the ratio of geometric means of two treatments fell completely within the limits of 0.8500-1.1765 for the primary PD parameters.

## Secondary PD Parameters

The secondary PD parameter to be determined or calculated from the cell count-time data for ANC was:

- ANC Tmax = Time of maximum change from baseline for ANC

The secondary PD parameters to be determined or calculated from the cell count-time data for CD34+ cell counts were:

- CD34+ AUC0-t = Area under the CD34+ cell counts above baseline versus time curve

<div style=\"page-break-after: always\"></div>

- CD34+ Cmax = Maximum change from baseline for CD34+ cell counts
- CD34+ Tmax = Time of maximum change from baseline

The choice of the primary and secondary PD parameters is in line with the respective guideline and acceptable.

## Determination of Sample Size

The actual sample size of 216 healthy volunteers was based on the following assumptions laid down in the protocol:

- -Intrasubject variability from the MYL-PER-0001 pilot study11 1 :
- ANC AUC0-t = 14%
- PEG-GCSF AUC0-t and AUC0-inf = 36%
- PEG-GCSF Cmax = 50%
- 95% CI
- equivalence range [0.8500-1.1765]
- ratio of geometric means in interval [0.95-1.05]
- -PEG-GCSF AUC0-t, AUC0-inf and Cmax
- 90% CI
- equivalence range [0.8000-1.2500]
- ratio of geometric means in interval [0.95-1.05]

It was estimated that with 180 evaluable subjects the study will have a combined power for PD and PK of over 90% to establish equivalence for each of the 3 pairwise comparisons.

According to the applicant, the sample size estimation was not literature derived but was based on a pilot study with Neulasta.

## Results

- Disposition of Subjects and Data Sets analysed

372 subjects were screened and 216 subjects were included in the study. All of these 216 subjects were randomised and received at least one dose of 2 mg pegfilgrastim. The doses of pegfilgrastim were administered at least 4 weeks apart. All 216 subjects were included in the safety analysis set.

Twenty subjects discontinued the study for the following reasons:

8 subjects were withdrawn because of a protocol violation (tested positive for cannabinoids and cocaine; inability to follow protocol instructions).

8 subjects withdrew consent for personal reasons.

3 subjects were withdrawn due to AEs (1 SAE).

1 A pilot phase 1, repeated single dose study evaluating the variability of pharmacokinetics and pharmacodynamics of long acting filgrastim following subcutaneous administration to healthy volunteers. Myl-Per0001/MYB262EC-122621. Final Clinical Study Report. 18 June 2013.

- -ANC AUC0-t:

<div style=\"page-break-after: always\"></div>

1 subject dropped out after dosing in Period 2 because he missed too many visits due to illness.

A total of 196 subjects completed the study as per protocol. All of these subjects were part of the 208 subjects who were included in both the PK and PD analysis sets.

Number and reasons for withdrawal were as expected. The about 10% withdrawal rate seems to equally distribute over the 6 sequences. As to the subjects withdrawn due to AEs or SAEs  see safety assessment.

- Baseline characteristics

Table 3: Summary of demographic characteristics (MYL-1401H-1001)

| Parameter               | Parameter                     | Statistic / Category       | Safety Set (N =216)    | PK and PD Set (N = 208)   |
|-------------------------|-------------------------------|----------------------------|------------------------|---------------------------|
| Gender                  | -Male                         | n (%)                      | 170 ( 79%)             | 163(78%)                  |
|                         | -Female                       | n (%)                      | 46 ( 21%)              | 45 (22%)                  |
| Ethnicity               | -Hispanic or Latino           | n (%)                      | 3( 1%)                 | 3( 1%)                    |
|                         | -NotHispanicor Latino         | n (%)                      | 213 ( 99%)             | 205 (99%)                 |
| Race                    | -AmericanIndianOrAlaskaNative | n (%)                      | 2( 1%)                 | 2(1%)                     |
|                         | - Asian                       | n (%)                      | 5 ( 2%)                | 5 ( 2%)                   |
|                         | -Black                        | n (%)                      | 6 ( 3%)                | 5 ( 2%)                   |
|                         | -White                        | n (%)                      | 196 (91%)              | 189 (91%)                 |
|                         | -Multiple                     | n (%)                      | 7( 3%)                 | 7( 3%)                    |
| Age (years)             |                               | mean (SD) median           | 37 (14) 33             | 37 (14) 33                |
| Weight (kg)             |                               | min - max mean (SD) median | 18-65 78.5 (10.7) 78.3 | 18-65 78.4 (10.8) 78.0    |
| Height (cm)             |                               | min-max mean (SD) median   | 59.4-106.5 178 (9) 179 | 59.4 - 106.5 178 (9) 179  |
|                         |                               | min-max                    | 156 -201               | 156-201                   |
| Body Mass Index (kg/m) |                               | mean (SD)                  | 24.6 (2.6)             | 24.6 (2.6)                |
|                         |                               | min-max                    | 19.5 -30.4             | 19.5 - 30.4               |

max = maximum; min = minimum; N (n) = number of subjects; PD = pharmacodynamics; PK=pharmacokinetics;SD=standard deviation

- Pharmacokinetic Results

## Concentration Data of PEG-GCSF in Serum

After administration of a single sc injection of 2 mg pegfilgrastim, PEG-GCSF (analyte) appeared in serum within 2 to 4 hours post-dose. Only for 2 of the 216 subjects, PEG-GCSF concentrations were first observed at 6 hours after dosing with EU-Neulasta.

The concentrations of PEG-GCSF in serum increased slowly, with maximum mean concentrations reached at approximately 12 hours post-dose.

Mean PEG-GCSF concentrations could be determined in serum up to 144 hours post-dose for all 3 treatments.

## Pharmacokinetic Parameters of PEG-GCSF in Serum

The exposure to PEG-GCSF (in terms of Cmax, AUC0-inf and AUC0-t) was most similar between MYL1401H and US-Neulasta, whereas the exposure of EU-Neulasta appeared to be slightly lower than the other 2 treatments (Table 4).

The median Tmax of PEG-GCSF in serum was 12 hours for all 3 treatments.

The geometric mean t1/2 of PEG-GCSF varied minimally between 49.3 and 51.1 hours across treatments.

The %AUCextra, Vd/F and kel were comparable between the 3 treatments.

<div style=\"page-break-after: always\"></div>

Considerable inter-subject variability was observed for the primary PK parameters Cmax and AUC0-inf of PEG-GCSF (CV% ~70%).

Table 4: Summary of PK parameters for PEG-GCSF in serum (geometric mean [CV%]) (MYL 1401H-1001)

| Parameter          | MYL-1401H N=204    | EU-Neulasta N=203   | US-Neulasta N=207   |
|--------------------|--------------------|---------------------|---------------------|
| Cmax (pg/mL)       | 36.7 (72.1%)       | 34.2 (72.1%)        | 37.3 (67.6%)        |
| AUCo-inf (hng/mL) | 869 (69.1%)        | 833 (70.1%)         | 876 (66.3%)         |
| AUCo-t (hng/mL)   | 827 (71.4%)        | 787 (72.7%)         | 832 (68.6%)         |
| %AUCextra (%)      | 3.2 (97.2%)        | 3.6 (97.9%)         | 3.2 (105.9%)        |
| Tmax (h)           | 12.00 (6.00-24.02) | 12.00 (6.00-48.00)  | 12.00 (4.02 -24.02) |
| Kel (1/h)          | 0.014 (31.0%)      | 0.014 (39.1%)       | 0.014 (40.1%)       |
| Va/F (L)           | 164 (100%)         | 177 (101%)          | 168 (113%)          |
| t1/2 (h)           | 49.3 (36.5%)       | 51.1 (48.9%)        | 51.0 (42.5%)        |

CV%=coefficient of variation;PK=pharmacokinetic

For Tmax the median (range) is presented.

## Statistical Analysis of Pharmacokinetic Equivalence

When comparing the primary PK parameters Cmax and AUC0-inf of PEG-GCSF between MYL-1401H, EU-Neulasta and US-Neulasta, GLM ANOVA results showed that the 90% CIs of the ratios of geometric means for these PK parameters ranged between 0.907 and 1.18. The 90% CIs were therefore well contained within the standard bioequivalence interval of 0.8000 - 1.2500 for each of the comparisons.

These results demonstrate similar PK profiles of MYL-1401H, EU-Neulasta and US-Neulasta. The intrasubject CV% (within-subject variability) for the primary PK parameters Cmax and AUC0-inf was 54.8% and 41.8%, respectively, across the 3 treatments.

Table 5: Summary of bioequivalence analysis on primary PK parameters of PEG-GCSF in serum (geometric mean [CV%]) (MYL-1401H-1001)

|                           |                    | Geometric LS means   | Geometric LS means   | RatioTest/Reference   | RatioTest/Reference   | RatioTest/Reference   |       |
|---------------------------|--------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|-------|
| TreatmentComparison       | PK                 |                      |                      |                       | 90%CI#                | 90%CI#                | Intra |
| (TestversusReference)     | Parameter          | Test                 | Reference            | Estimate              | Lower                 | Upper                 | CV%   |
| MYL-1401H/EU-Neulasta     | Cmax (pg/mL)       | 36.6                 | 34.2                 | 1.07                  | 0.984                 | 1.16                  | 54.8* |
|                           | AUCo-inf (hng/mL) | 871                  | 835                  | 1.04                  | 0.977                 | 1.11                  | 41.8* |
| MYL-1401H/US-Neulasta?    | Cmax (pg/mL)       | 36.6                 | 37.2                 | 0.986                 | 0.907                 | 1.07                  |       |
|                           | AUCo-inf (hng/mL) | 871                  | 873                  | 0.998                 | 0.935                 | 1.07                  |       |
| US-Neulasta/ EU-Neulasta? | Cmax (pg/mL)       | 37.2                 | 34.2                 | 1.09                  | 0.998                 | 1.18                  |       |
|                           | AUCo-inf (hng/mL) | 873                  | 835                  | 1.05                  | 0.979                 | 1.12                  |       |

CI=confidence interval;intraCV%=intra-subject coefficient ofvariation;LS=leastsquares;

PK = pharmacokinetic

Natural log transformation of Cmax and AUCo-inf was used for analysis. Using PROC general linear model (GLM) analysis of variance (ANOVA) with treatment,sequence and period asfixed effects,and subject within sequence as a random effect.

* The intra CV% (within-subject variability) is displayed only once for each parameter, as it is equal for eachcomparison.

# Bioequivalence is established if the 90% Cl of the ratio is contained completely within acceptance range (0.800 - 1.2500).

## Relationship between Pharmacokinetics and Anti-Drug Antibodies

Descriptive statistics were used to summarise the serum PEG-GCSF concentrations and PK parameters by treatment and ADA status as defined as follows.

<div style=\"page-break-after: always\"></div>

- ADA positive: Subjects with any confirmed positive ADA response against PEG G-CSF at any point during the study
- ADA negative: Subjects with no confirmed positive ADA response against PEG G-CSF at any point during the study

In addition, geometric mean ratios and corresponding 90% CIs for the 3 pairwise comparisons between 2 treatments were repeated by ADA status for the primary and secondary PK parameters.

Minimal differences (10%) in the exposure to PEG -GCSF were observed between ADA positive and negative subjects. For MYL-1401H treatment the geometric mean AUC0-inf was approximately 1.1-fold higher in ADA positive subjects (932 hng/mL; n=62) than in ADA negative subjects (843 hng/mL; n=142), whereas for EU-Neulasta the AUC0-inf was approximately 1.1-fold lower in ADA positive (775 hng/mL; n=62) than in ADA negative subjects (860 hng/mL; n=141). For US-Neulasta the differences in exposure were less than 5% between ADA positive (857 hng/mL; n=64) and negative subjects (885 hng/mL; n=143).

When excluding the ADA positive subjects from the comparison of the primary PK parameters Cmax and AUC0-inf of PEG-GCSF between the 3 treatments, results showed that the upper limit of the 90% CIs of the geometric means ratios were still contained within 0.8000 - 1.2500 bioequivalence interval for each comparison.

## 6.2.2.3. Distribution

Same as for the reference product.

## 6.2.2.4. Metabolism

Same as for the reference product.

## 6.2.2.5. Elimination

Same as for the reference product.

## 6.2.2.6. Dose proportionality and time dependency

Same as for the reference product.

## 6.2.2.7. Pharmacokinetics in the target population

Same as for the reference product.

## 6.2.2.8. Special populations

Same as for the reference product.

## 6.2.2.9. Pharmacokinetic interaction studies

Same as for the reference product.

## 6.2.3. Pharmacodynamics

## 6.2.3.1. Mechanism of action

Same as for the reference product.

<div style=\"page-break-after: always\"></div>

## 6.2.3.2. Primary and secondary pharmacology

## Study MYL-1401H-1001

## Concentration Data of ANC and CD34+ in Serum ANC

After administration of a single SC injection of 2 mg MYL-1401H, EU-Neulasta or US-Neulasta, mean ANC levels above baseline were first observed at 4 hours post-dose on Day 1. For all 3 treatments, a similar peak increase of approximately 8-fold compared to baseline was observed between Day 2 and Day 3 (24-48 hours post-dose; see Figure 2).

Figure  2:  Arithmetic  mean  change  from  baseline  ANC  serum  concentration-time  profiles (MYL-1401H-1001)

<!-- image -->

Hours

<!-- image -->

Hours

Thereafter the mean ANC appeared to decrease in a multiphasic manner, with a relatively slow elimination phase between Day 6 and Day 9 (between 120 and 192 hours post-dose), before the ANC returned to values near baseline on Day 12 (264 hours post-dose). The mean ANC versus time profiles were very similar between the 3 treatments.

The combined individual change from baseline ANC versus time profiles showed minimal interindividual variability. However, for 2 subjects the increase in the ANC was very low (approximately 2fold compared to baseline) after administration of US-Neulasta in Period 2 compared to the other subjects. These minimal ANC increases were consistent with the relatively low PEG-GCSF concentrations observed for these subjects.

Mean CD34+ counts above baseline were first observed on Day 3. A maximum increase of approximately 9.5-fold compared to baseline was observed on Day 5 (96 hours post-dose; Figure 3). Thereafter the mean CD34+ counts decreased to values near baseline on Day 12. The mean CD34+ versus time profiles were very similar between the 3 treatments.

<div style=\"page-break-after: always\"></div>

The combined individual change from baseline CD34+ counts versus time profiles showed considerable inter-individual variability in the extent of increase in CD34+ counts over time.

Figure 3: Arithmetic mean change from baseline CD34+ serum concentration-time profiles (MYL-1401H-1001)

<!-- image -->

<!-- image -->

The primary PD parameters ANC Cmax and ANC AUC0-t were very similar across treatments. Also the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t were comparable between these treatments.

For MYL-1401H and EU-Neulasta the median ANC Tmax was 48 hours and for US-Neulasta the median ANC Tmax was 24 hours. For the CD34+ counts, the median CD34+ Tmax was 96 hours for all 3 treatments.

The inter-subject variability was much higher for the secondary CD34+ PD parameters (CV% up to ~80%) than for the primary ANC PD parameters (CV% up to ~30%).

<div style=\"page-break-after: always\"></div>

Table 6: Summary of PD parameters for ANC and CD34+ count data (geometric mean [CV%]) (MYL-1401H-1001)

| Parameter                 | MYL-1401H N=204       | EU-Neulasta? N=203   | N=207                  |
|---------------------------|-----------------------|----------------------|------------------------|
| ANC PD Parameters         | ANC PD Parameters     | ANC PD Parameters    | ANC PD Parameters      |
| ANC AUCo-t (h10%/L)      | 2784.356 (29.0%)      | 2792.623 (30.7%)     | 2744.700 (30.8%)       |
| ANC Cmax (10%/L)          | 22.507 (25.7%)        | 22.686 (25.9%)       | 22.546 (26.4%)         |
| ANC Tmax (h)              | 47.98 (12.00 - 96.00) | 48.00 (12.00 -96.00) | 24.05 (8.00 - 72.03)   |
| CD34+PDParameters         | CD34+PDParameters     | CD34+PDParameters    | CD34+PDParameters      |
| CD34+ AUCo-t (hcells/L) | 1652.305 (79.7%)      | 1633.532 (81.0%)     | 1598.443 (81.2%)       |
| CD34+ Cmax (cells/L)     | 17.469 (76.5%)        | 17.681 (77.0%)       | 17.445 (77.1%)         |
| CD34+ Tmax (h)            | 96.00 (71.97 -168.00) | 96.02 (72.00-192.00) | 96.00 (48.00 - 192.00) |

ANC = absolute neutrophil count; CV% = coefficient of variation; PD = pharmacodynamic

For Tmax the median (range) is presented.

- Statistical Analysis of Pharmacodynamic Equivalence

## Primary PD Parameters

When comparing the primary PD parameters ANC AUC0-t and ANC Cmax between the 3 treatments (MYL-1401H, EU-Neulasta and US-Neulasta), GLM ANOVA results showed that the 95% CIs of the ratios of geometric means for these PD parameters ranged between 0.943 and 1.061 for each of the comparisons. The 95% CIs were therefore well contained within the predefined equivalence interval of 0.8500 - 1.1765 for each of the comparisons. Likewise, the 90% CIs ranging between 0.950 and 1.054 were well contained within the 0.80 - 1.25 similarity range which was conducted as additional analysis. The intra-subject CV% was low for the primary PD parameters and comparable between ANC AUC0-t (22.3%) and ANC Cmax (17.7%).

<div style=\"page-break-after: always\"></div>

Table 71: Summary of equivalence analysis for the primary PD parameters for ANC (MYL1401H-1001)

|                             |                       | Geometric LS means   | Geometric LS means   | RatioTest/Reference   | RatioTest/Reference   | RatioTest/Reference   |       |
|-----------------------------|-----------------------|----------------------|----------------------|-----------------------|-----------------------|-----------------------|-------|
| Treatment Comparison        | PD                    |                      |                      |                       | 95% CI #              | 95% CI #              | Intra |
| (Test versus Reference)     | Parameter             | Test                 | Reference            | Estimate              | Lower                 | Upper                 | CV%   |
| MYL-1401H/ EU-Neulasta      | ANC AUCo-t (h10/mL)  | 2794.628             | 2791.608             | 1.001                 | 0.959                 | 1.045                 | 22.3* |
|                             | ANC Cmax (10%/mL)     | 22.539               | 22.687               | 0.993                 | 0.960                 | 1.028                 | 17.7* |
| MYL-1401H / US-Neulasta?    | ANC AUCo-t (h10%/mL) | 2794.628             | 2747.813             | 1.017                 | 0.974                 | 1.061                 |       |
|                             | ANC Cmax (10%/mL)     | 22.539               | 22.542               | 1.000                 | 0.966                 | 1.035                 |       |
| US-Neulasta@ / EU-Neulasta? | ANC AUCo-t (h10/mL)  | 2747.813             | 2791.608             | 0.984                 | 0.943                 | 1.027                 |       |
|                             | ANC Cmax (10%/mL)     | 22.542               | 22.687               | 0.994                 | 0.960                 | 1.028                 |       |

ANC = absolute neutrophil count; Cl = confidence interval; intra CV% = intra-subject coefficient of variation; LS = least squares; PD = pharmacodynamic

Natural log transformation of Cmax and AUCo-t was used for analysis. PROC general linear model (GLM) analysis of variance (ANOVA) with treatment sequence and period as fixed effects, and subject within sequence as a random effect was performed for these parameters.

Equivalence is established if the 95% Cl of the ratio is contained completely within acceptance range (0.8500 - 1.1765).

each comparison.

## Secondary PD Parameters

The estimates and corresponding 95% CIs of the geometric mean ratios were close to 1 for the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t, with 95% CIs ranging between 0.915 and 1.104 for each of the comparisons. The intra-subject variability was comparable between CD34+ Cmax (33.7%) and CD34+ AUC0-t (34.1%) across the 3 treatments. For the secondary PD parameters ANC Tmax and CD34+ Tmax, all estimates and corresponding 95% CIs were zero (0.000).

<div style=\"page-break-after: always\"></div>

Table 8: Summary of statistical analysis on secondary PD parameters for ANC and CD34+ count data (MYL-1401H-1001)

|                            |                            | Median                     | Median                     | Test Minus Reference       | Test Minus Reference       | Test Minus Reference       |
|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| Treatment Comparison       |                            |                            |                            |                            | 95% CI                     | 95% CI                     |
| (Test versus Reference)    | PD Parameter               | Test                       | Reference Estimate         |                            | Lower                      | Upper                      |
| Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter | Secondary ANC PD Parameter |
| MYL-1401H/ EU-Neulasta     | ANC Tmax (h)               | 47.975                     | 48.000                     | 0.000                      | 0.000                      | 0.000                      |
| MYL-1401H / US-Neulasta   | ANC Tmax (h)               | 47.975                     | 24.050                     | 0.000                      | 0.000                      | 0.000                      |
| US-Neulasta/ EU-Neulasta   | ANC Tmax (h)               | 24.050                     | 48.000                     | 0.000                      | 0.000                      | 0.000                      |
| Secondary CD34+Parameter   | Secondary CD34+Parameter   | Secondary CD34+Parameter   | Secondary CD34+Parameter   | Secondary CD34+Parameter   | Secondary CD34+Parameter   | Secondary CD34+Parameter   |
| MYL-1401H/EU-Neulasta      | CD34+Tmax (h)              | 96.000                     | 96.020                     | 0.000                      | 0.000                      | 0.000                      |
| MYL-1401H/ US-Neulasta     | CD34+Tmax (h)              | 96.000                     | 96.000                     | 0.000                      | 0.000                      | 0.000                      |
| US-Neulasta/ EU-Neulasta   | CD34+Tmax                  | 96.000                     | 96.020                     | 0.000                      | 0.000                      | 0.000                      |

(h)

|                              |                              | Geometric LS means           | Geometric LS means           | Ratio Test/Reference         | Ratio Test/Reference         | Ratio Test/Reference         |                              |
|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
| Treatment Comparison         |                              |                              |                              |                              | 10 %96                       | 10 %96                       | Intra                        |
| (Test versus Reference)      | PD Parameter                 | Test                         | Reference                    | Estimate                     | Lower                        | Upper                        | CV%                          |
| Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters | Secondary CD34+PD Parameters |
| MYL-1401H/ EU-Neulasta       | CD34+ Cmax (cells/L)        | 17.670                       | 17.701                       | 0.998                        | 0.936                        | 1.065                        | 33.7*                        |
|                              | CD34+AUCot (hcells/L)      | 1655.336                     | 1638.707                     | 1.010                        | 0.946                        | 1.078                        | 34.1*                        |
| MYL-1401H / US-Neulasta      | CD34+ Cmax (cells/L)        | 17.670                       | 17.428                       | 1.014                        | 0.951                        | 1.081                        |                              |
|                              | CD34+AUC (h-cells/L)        | 1655.336                     | 1600.001                     | 1.035                        | 0.970                        | 1.104                        |                              |
| US-Neulasta/ EU-Neulasta    | CD34+ Cmax (cells/L)        | 17.428                       | 17.701                       | 0.985                        | 0.924                        | 1.050                        |                              |
|                              | CD34+AUC (hcells/L)        | 1600.001                     | 1638.707                     | 0.976                        | 0.915                        | 1.042                        |                              |

ANC = absolute neutrophil count; Cl = confidence interval; intra CV% = intra-subject coefficient of variation; LS = least squares; PD = pharmacodynamic

Natural log transformation of Cmax and AUCot was used for analysis. PRoC general linear model (GLM) analysis of variance (ANoVA) with treatment sequence and period as fixed effects, and subject within sequence as a random effect was perfomed for these parameters.

For Tmax a non-parametric Hodges-Lehmann method was perfomed on the non-transfomed values. + The intra CV% (within-subject variability) is displayed only once for each parameter, as it is equal for each comparison.

##  Relationship between Pharmacodynamics and Anti-Drug Antibodies

Descriptive statistics were used to summarise the PD parameters for ANC and CD34+ count by treatment and ADA status.

In addition, geometric mean ratios and corresponding 95% CIs for the 3 pairwise comparisons between 2 treatments were repeated by ADA status for the primary PD parameters for ANC and secondary PD parameters for ANC and CD34+ count data.

Minimal differences in the PD response were observed between ADA positive and negative subjects. For all 3 treatments, the primary PD response in terms of ANC AUC0-t appeared to be approximately 10% lower in ADA positive subjects compared to in ADA negative subjects.

<div style=\"page-break-after: always\"></div>

When excluding the ADA positive subjects from the comparison of the primary PD parameters in terms of ANC Cmax and ANC AUC0-t between the 3 treatments, results showed that the upper limit of the 95% CIs of the geometric means ratios were still contained within 0.8500 - 1.1765 equivalence interval for each comparison (Table 9).

Still in the smaller ADA positive subgroup the equivalence margin was met for the primary PD parameters. Also for the secondary PD parameters in this ADA negative subgroup, the estimates and corresponding 95% CIs of the geometric mean ratios were close to 1 for CD34+ Cmax and CD34+ AUC0-t, and the median difference was zero (0.000) for ANC Tmax and CD34+ Tmax.

Table 9: Summary of equivalence analysis for the primary PD parameters for ANC in ADA negative subjects (MYL-1401H-1001)

|                            |                        | GeometricLSmeans   | GeometricLSmeans   | RatioTest/Reference   | RatioTest/Reference   | RatioTest/Reference   |       |
|----------------------------|------------------------|--------------------|--------------------|-----------------------|-----------------------|-----------------------|-------|
| Treatment Comparison       | PD                     |                    |                    |                       | 95% CI#               | 95% CI#               | Intra |
| (TestversusReference)      | Parameter              | Test               | Reference          | Estimate              | Lower                 | Upper                 | CV%*  |
| MYL-1401H/EU-Neulasta?     | ANC AUCo-t (h10%/mL)  | 2849.073           | 2892.386           | 0.985                 | 0.945                 | 1.027                 | 17.9  |
|                            | ANC Cmax (10%/mL)      | 22.675             | 22.945             | 0.988                 | 0.958                 | 1.020                 | 13.4  |
| MYL-1401H / US-Neulasta?   | ANC AUCo-t (h10%/mL)  | 2849.073           | 2840.594           | 1.003                 | 0.962                 | 1.046                 |       |
|                            | ANC Cmax  (10%/mL)     | 22.675             | 23.090             | 0.982                 | 0.952                 | 1.013                 |       |
| US-Neulasta?/ EU-Neulasta? | ANC AUCo-t  (h10%/mL) | 2840.594           | 2892.386           | 0.982                 | 0.942                 | 1.024                 |       |
|                            | ANC Cmax (10%/mL)      | 23.090             | 22.945             | 1.006                 | 0.975                 | 1.038                 |       |

ADA= anti-drugantibodies;ANC=absoluteneutrophilcount;Cl= confidence interval; intra CV%= intra-subject coefficient of variation; LS = least squares; PD = pharmacodynamic

Natural log transformation of Cmax and AUCo-t was used for analysis. PROC GLM (general linear model)analysisofvariance(ANOvA) withtreatment sequence and period as fixedeffects,and subject withinsequenceasarandomeffectwasperformedfortheseparameters.

study.

# Equivalence is established if the 95% Cl of the ratio is contained completely within acceptance range (0.8500 - 1.1765).

* The intra Cv% (within-subject variability) is displayed only once for each parameter, as it is equal for each comparison.

## Study MYL-1401H-1002

Trial MYL-1401H-1002 was a single-centre, randomised, open-label, repeated dose, parallel group trial intended to evaluate immunogenicity, PD, safety, and tolerability of the test product, MYL1401H, compared with the reference product, US-licensed Neulasta, in healthy subjects.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 4 : Study design (MYL-1401-1002)

<!-- image -->

Each subject received 2 single sc. injections of 6 mg of either the test product, MYL-1401H, or the reference product, US-Neulasta, in 2 separate periods with a washout period of 4 weeks between study drug administrations. The sc. injections were given using a prefilled syringe.

As primary objective the immunogenicity between two sc injections of MYL-1401H and US Neulasta was descriptively compared. As secondary objective the safety and tolerability of MYL-1401H and US Neulasta after two sc injections (6 mg) in healthy volunteers was evaluated.

The sample size estimation is based on an 'expected immunogenicity event rate' as follows:

The expected immunogenicity event rate in this study was 13%. A total sample size of 44 normal healthy volunteers (22 per group) would provide 95% confidence to rule out an immunogenicity event rate of 13% or more in each treatment group if no events are observed.

## Results

##  Disposition of Subjects and Data Sets Analysed

Of the 85 subjects who were screened, 50 subjects were included in the study. Of these, 25 subjects received 6 mg MYL-1401H and 25 subjects received 6 mg US-Neulasta in the first treatment period. After dosing in Period 1, 6 subjects were withdrawn due to non-serious TEAEs. As a result, 23 of 25 subjects who received 6 mg MYL-1401H in the first treatment period received the same dose in the second treatment period, and 21 of 25 subjects who received 6 mg US-Neulasta in the first treatment period received the same dose in the second treatment period. In addition, one subject withdrew consent in the second treatment period after receiving the second dose of US-Neulasta. A total 43 subjects completed the study and all were included in the PP set. The subject who withdrew consent after completion of dosing in Period 2 was included in the PP set as well, which consisted of 44 subjects in total. All 50 dosed subjects were included in the SAF set.

There were a few protocol deviations that were considered minor and not having affected the outcome of the study.

<div style=\"page-break-after: always\"></div>

##  Demographic and Other Baseline Characteristics

Based on Table 10, demographic characteristics are comparable between treatment groups.

Table 10: Summary of demographic characteristics (safety set)

| Parameter               | Parameter                        | Statistic / Category   | MYL-1401H (N=25)       | US-Neulasta (N=25)         | Total (N=50)            |
|-------------------------|----------------------------------|------------------------|------------------------|----------------------------|-------------------------|
| Gender                  | - Male                           | n (%)                  | 13 (52.0)              | 11 (44.0)                  | 24 (48.0)               |
|                         | - Female                         | n (%)                  | 12 (48.0)              | 14 (56.0)                  | 26 (52.0)               |
| Race                    | American Indian or Alaska Native | n (%)                  | 0 (0.0)                | 1 (4.0)                    | 1 (2.0)                 |
|                         | Asian                            | n (%)                  | 1 (4.0)                | 0 (0.0)                    | 1 (2.0)                 |
|                         | Black or African American        | n (%)                  | 1 (4.0)                | 0 (0.0)                    | 1 (2.0)                 |
|                         | White                            | n (%)                  | 20 (80.0)              | 22 (88.0)                  | 42 (84.0)               |
|                         | - Multiple                       | n (%)                  | 3 (12.0)               | 2 (8.0)                    | 5 (10.0)                |
| Ethnicity               | Hispanic or Latino               | n (%)                  | 0 (0.0)                | 1 (4.0)                    | 1 (2.0)                 |
| Age (years)             | Age (years)                      | mean (SD) min - max    | 34.7 (14.64) 19 -65    | 41.4 (15.76) 19 - 64       | 38.0 (15.42) 19 -65     |
| Height (cm)             | Height (cm)                      | mean (SD) min-max      | 178.4 (11.36) 153 -200 | 173.4 (8.47) 157-193       | 175.9 (10.23) 153 - 200 |
| Weight (kg)             | Weight (kg)                      | mean (SD)              | 75.9 (11.85)           | 74.4 (11.62)               | 75.2 (11.64)            |
|                         |                                  | min-max                | 62 -113                | 60 - 106                   | 60 -113                 |
| Body Mass Index (kg/m) | Body Mass Index (kg/m)          | mean (SD)              | 23.82 (2.40)           | 24.66 (2.61) 19.60 - 29.00 | 24.24 (2.52)            |
|                         |                                  | min-max                | 20.60 - 28.50          |                            | 19.60 - 29.00           |

max = maximum; min = minimum; N (n) = number of subjects; SD = standard deviation

##  Pharmacodynamic Results

Samples for determination of ANC were taken each period on Day -1 (as part of the clinical laboratory assessments), on Days 2 (as part of the clinical laboratory assessments), 3, 8, 15, and 22, and at follow-up (as part of the clinical laboratory assessments). The Day 3 assessment was expected to be close to the time of maximum potential drug effect on ANC.

The mean ANC versus time profiles were relatively similar between the 2 treatments. An ANC elevation was observed at the first sampling time point of 24 hours after dosing of either the test product, MYL-1401H, or the reference product, US-Neulasta. The strongest ANC response was observed 48 hours after the second dose; ANC levels were approximately 9-fold higher for both treatments compared with baseline. On subsequent days, ANC levels decreased and had returned to normal by 14 days after dosing. CD34+ counting was not performed.

<div style=\"page-break-after: always\"></div>

Figure 5:  Mean absolute neutrophil count versus time by treatment (per-protocol set)

<!-- image -->

## 6.2.4. Overall discussion and conclusions on clinical pharmacology

## 6.2.4.1. Discussion

Study MYL-1401H-1001 demonstrated in an appropriate and sensitive model in a confirmatory way that 2 mg MYL-1401H and 2 mg reference MP (Neulasta EU sourced) were equivalent in terms of PK profiles and the co-primary PD endpoints ANC AUC0-t and ANC Cmax. This study also showed PD equivalence as to CD34+ count as a secondary parameter.

There were small differences in the PD response observed between ADA positive and negative subjects where responses in terms of ANC AUC0-t appeared to be approximately 10% lower in ADA positive subjects compared to in ADA negative subjects. Although the study MYL-1401H-1001 was not powered to evaluate equivalence of the primary PD parameters for ANC in a smaller subgroup of ADA negative subjects, these results indicate that the primary PD parameters continued to be equivalent between MYL-1401H and the reference treatments EU-Neulasta and US-Neulasta in a subgroup of subjects without any ADA positive response at any time point. Also the secondary PD parameters appeared to be similar between MYL-1401H and the reference treatments in this subgroup.

PD was also descriptively analysed in trial MYL-1401H-1002. The results reasonably support those of study 1001. In this study US-sourced Neulasta was used. The study results are relevant for the current application because an analytical bridge between US- and EU-sourced reference product has been established.

The applicant did not submit studies on distribution, elimination, dose-proportionality and time dependencies, special populations, pharmacokinetics interaction studies, pharmacokinetics using biomaterials and mechanism of action. This is acceptable as according to the guideline EMEA/CHMP/BMWP/31329/2005, these studies are not required.

Taken together, these results support the claim of biosimilarity between Vivlipeg and the reference product Neulasta.

<div style=\"page-break-after: always\"></div>

## 6.2.4.2. Conclusions

The clinical pharmacology has been well described for Vivlipeg and the claim of biosimilarity is supported by the primary and secondary PK parameters which were fully contained within the acceptance interval of 80.00-125.00% in the study MYL-1401H-1001 as well as the secondary PD parameters where the GMR were close to 1.

Study MYL-1401H-1002 was supportive of the claim for biosimilarity.

Therefore, overall PK/PD data from the two studies show that similarity between Vivlipeg and the reference product Neulasta could be demonstrated.

## 6.3. Clinical efficacy

## 6.3.1. Dose response study(ies)

No specific dose-response studies were submitted with the initial application. The applicant selected the dose based on the approved one for US- and EU-Neulasta a fixed SC dose of 6 mg, once per cycle.

## 6.3.2. Main study

## 6.3.2.1. MYL-1401H-3001

## 6.3.2.1.1. Study title

A Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.

## 6.3.2.1.2. Study design

MYL-1401H 6 mg injection administered as a single sc dose, on Day 2 of each cycle, i.e., 24 h (+ 2 h after) after the end of chemotherapy.

The planned duration for the entire study was approximately 28 weeks (from Screening to follow-up [24 weeks from the first dose of study drug]), assuming no delays in dosing.

The planned duration of patient treatment during the entire study was approximately 18 weeks (from the first day of chemotherapy [Day 1 Cycle 1] to the last scheduled assessment in Cycle 6), assuming no delays in dosing.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations: CTX = cytotoxic chemotherapy; mg = milligram; n = chemotherapy cycle; sc = subcutaneous; w = weeks

Figure 6: Overview of study design MYL-1401H-3001

## Randomisation

Patients were randomised to receive either MYL-1401H or EU-Neulasta (in a 2:1 ratio, respectively), and were stratified based on their age and country.

## Blinding (masking)

The oncology pharmacist who prepared the doses and the person administering the drug (e.g., study nurse, physician [other than the principal investigator or sub-principal investigator]) were the only individuals who had access or knowledge of the actual drug delivered. When administering the drug, the application syringes were covered in order to make them indistinguishable to the patient.

## 6.3.2.1.2.1. Patient population

## Inclusion criteria

1. Patients aged 18 years.
2. Women of child-bearing potential agreed to use effective methods of birth control during the treatment period from the first dose of study drug until 6 months following the last dose of study drug. Acceptable methods of contraception included nonhormonal intrauterine device and barrier methods (male condom, female condom, diaphragm, or cervical cap) with spermicide. Female patients who normally abstained from sexual activity were recruited, provided that they remained abstinent during the study or if they became sexually active, they agreed to use effective methods of birth control as described above.
3. Male patients without a vasectomy agreed to use a condom and their female partners of childbearing potential agreed to use another form of contraception (hormonal contraceptives, intrauterine device, diaphragm with spermicide, or cervical cap with spermicide) during the treatment period from the first dose of study drug until 6 months following the last dose of study drug.

<div style=\"page-break-after: always\"></div>

4. Newly diagnosed, pathologically confirmed breast cancer. Stage II or III breast cancer with adequate staging workup (National Comprehensive Cancer Network guidelines; Version 1.2014) and adequate surgery if receiving adjuvant therapy.
5. Patients planned/eligible to receive neoadjuvant or adjuvant treatment with TAC for their breast cancer. Cancer chemotherapy and radiotherapy nave.
6. Eastern Cooperative Oncology Group (ECOG) performance status 1.
7. Absolute neutrophil count 1.5  10 9 /L.
8. Platelet count 100  10 9 /L.
9. Haemoglobin &gt;10 g/dL without blood transfusions or cytokine support during the 2 weeks previous to the haemoglobin level.
10. Adequate cardiac function (including left ventricular ejection fraction 50% as assessed by echocardiography) within 4 weeks prior to start of chemotherapy.
11. Adequate renal function, i.e. , creatinine &lt;1.5  upper limit of normal (ULN).

## Exclusion criteria

1. Participation in a clinical trial in which they received an investigational drug within 28 days before randomisation.
2. Previous exposure to filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, or other filgrastims on the market or in clinical development.
3. Received blood transfusions or erythroid growth factors within 2 weeks prior to first dose of chemotherapy.
4. Known hypersensitivity to any drugs or excipients that patients received during the study.
5. Known hypersensitivity to E. coli -derived products.
6. Known fructose intolerance (related with sorbitol excipient).
7. Underlying neuropathy of Grade 2 or higher.
8. Active infectious disease or any other medical condition which might have put the patient at significant risk to tolerate 6 courses of TAC chemotherapy (e.g., recent myocardial infarction).
9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5  ULN, ALT and/or AST &gt;1.5  ULN with alkaline phosphatase (ALP) &gt;2.5  ULN; any bilirubin &gt;ULN. Any alteration of liver function and/or ALP elevation, even within acceptance limits, was investigated before randomisation to exclude any Stage IV disease.
10. Treatment with systemically active antibiotics within 5 days before first dose of chemotherapy.
11. Patients under treatment with lithium.
12. Chronic use of oral corticosteroids.
13. Splenomegaly of unknown origin by physical examination and/or computerised tomography scan or ultrasound and any condition which can cause splenomegaly, e.g., thalassemia, glandular fever, haemolytic anaemias, and malaria.
14. Myeloproliferative or myelodysplastic disorders, sickle cell disorders, and any illness or condition that in the opinion of the investigator might affect the safety of the patient or the evaluation of any study endpoint.

<div style=\"page-break-after: always\"></div>

15. Increased potential risk of Adult Respiratory Distress Syndrome.
16. Pregnant or nursing women.
17. Patients known to be seropositive for human immunodeficiency virus, or having an acquired immunodeficiency syndrome defining illness or a known immunodeficiency disorder.
18. A known active abuse of drugs or alcohol precluded patient participation and evaluation in the study.
19. Any known psychiatric conditions.
20. Any disease or physical condition that would have interfered with adequate performance of study assessments, such as lack of access to patient's domiciliary, and distance of patient's domiciliary from clinic site.

## 6.3.2.1.3. Objectives and endpoints

The primary objective of this clinical trial was to compare the efficacy of MYL-1401H versus Europeansourced Neulasta (EU-Neulasta) for the prophylactic treatment of chemotherapy-induced neutropenia in patients with Stage II/III breast cancer receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) anti-cancer chemotherapy.

The secondary objectives of this clinical trial were as follows:

- to assess the safety of MYL-1401H and EU-Neulasta when administered through 6 cycles of TAC anti-cancer chemotherapy.
- to assess the potential immunogenicity of MYL-1401H and EU-Neulasta during chemotherapy and up to 24 weeks following the first administration.

## Primary Efficacy Endpoint:

The primary efficacy endpoint was the duration of severe neutropenia (DSN) in Cycle 1, defined as days with ANC &lt;0.5  10 9 /L.

## Secondary Efficacy Endpoints:

- [ ]  The frequency of the worst grade (Grade 3 or 4) neutropenia by cycle (Grade 3 defined as ANC &lt;1.0  10 9 /L and Grade 4 as ANC &lt;0.5  10 9 /L).

-  The depth of the ANC nadir in Cycle 1.

-  The time to the post- nadir ANC recovery (ANC 1.5  10 9 /L) in Cycle 1.

- [ ]  The ANC-time to nadir in Cycle 1 (i.e., time from the beginning of chemotherapy to the occurrence of the ANC nadir).

- [ ]  The rate of febrile neutropenia (FN) defined by the European Society of Medical Oncology Clinical Practice Guidelines as ANC &lt;0.5  109/L, or expected to fall below 0.5  109/L, with a single oral temperature &gt;38.5C or 2 consecutive readings of an oral temperature &gt;38.0C for 2 h, by cycle and across all cycles.

- [ ]  The percentage of scheduled chemotherapy doses that were delivered.

- [ ]  The proportion of chemotherapy doses reduced, omitted, or delayed related to neutropenia, FN, or documented infections.

- [ ]  The number of days of delay of chemotherapy related to neutropenia, FN, or documented infection.

<div style=\"page-break-after: always\"></div>

Safety:

The following safety endpoints were evaluated:

 The incidence, nature, and severity of adverse events (AEs) including adverse drug reactions.

 The incidence, severity, and distribution of bone pain by brief pain inventory (BPI) form (Short Form) in Cycle 1 and Cycle 2 only.

 The incidence, severity, and distribution of infections.

 Injection site tolerance.

-  Incidence, titre, and neutralizing capacity of antibodies against MYL-1401H and EU-Neulasta.

## 6.3.2.1.4. Sample size

Approximately 189 patients were planned for enrolment into the study in a 2:1 ratio of the 2 treatment groups (126:63 in the MYL-1401H and EU-Neulasta arm, respectively).

A total sample size of 135 patients allocated in a 2:1 ratio (90 and 45 patients treated with MYL-1401H and Neulasta, respectively) is required to provide 90% power to declare that MYL-1401H is comparable to Neulasta in the analysis of DSN in cycle 1. This sample size assumes that the mean DSN will be 1.70 days in cycle 1 for both MYL-1401H and Neulasta.

The common SD is assumed to be 1.5 days. Equivalence will be declared if the two-sided 95% confidence interval (CI) of the difference between the mean DSNs falls wholly within a region defined as [-1, +1 day].

The region of [-1, +1 day] was established by analysing historical Neulasta data and estimating a 50% retention of the Neulasta mean treatment benefit over placebo.

## 6.3.2.1.5. Statistical methods

The ITT Population (ITT) consisted of all patients who were randomised into the study. Patients in the ITT population were categorised to the treatment as-randomised.

The per protocol (PP) population was defined at the end of Cycle 1 and was a subset of the ITT, including patients receiving treatment to which they were randomised and had no major protocol deviations.

The primary efficacy analysis was based on the PP population, an in the ITT as a sensitivity analysis.

An ANOVA model with treatment as independent variable, and country and age-group as factors, was used to produce a 2-sided 95% CI for the difference in least squares means DSNs. Equivalence was declared if the CI was completely within the range of  1 day.

The difference in mean DSN in Cycle 1 within the PP population was statistically compared with the following hypotheses:

H0: (  MYL-1401H Neulasta  -1) or (  MYL-1401H Neulasta 1)

H1: -1 day &lt;(  MYL-1401H  Neulasta) &lt;1 day, where  MYL -1401H and Neulasta are the mean DSN for MYL -1401H and EU-Neulasta, respectively; calculated in days.

An analysis of variance (ANOVA) model with treatment as an independent variable, and country and age-group as factors, was used to produce a 2-sided 95% confidence interval (CI) for the difference in

<div style=\"page-break-after: always\"></div>

least squares mean (LS Mean) DSNs. The 2-sided 95% CI is equivalent to two 1-sided tests at the 2.5% level. Equivalence was declared if the CI was completely within the range of  1 day.

Secondary endpoints were analysed descriptively.

A blinded interim analysis was conducted when 50% of the required patients had completed cycle 1. If the common SD had been estimated to be &gt; 1.5 days, then the sample size would have been adjusted accordingly. Since this evaluation is blinded, there was no impact on the overall type 1 error rate and no adjustment of the final analysis of the primary objective was required according to the applicant. Because the SD was less than 1.5 days, no adjustment to the sample size was made.

## 6.3.2.1.6. Results

## 6.3.2.1.6.1. Participant flow and numbers analysed

<!-- image -->

Abbreviations: EU = European Union; ITT = intent to treat; N = number of patients

Actual: 194 patients were randomised and received study treatment; 127 patients were randomised to receive MYL-1401H and 67 patients were randomised to receive EU-Neulasta.

Completed: 186 patients completed the study.

Analysed: 194 patients were included in the data analysis.

## Numbers analysed

## ITT Population:

The ITT population consisted of all patients who were randomised into the study. The ITT population consisted of a total of 194 (100%) patients.

<div style=\"page-break-after: always\"></div>

Safety Population:

The safety population included all patients who received at least 1 dose of study drug and consisted of 194 (100%) patients.

Per Protocol Population:

The PP population was defined at the end of Cycle 1 and included a subset of the ITT population who started treatment without major protocol deviations and consisted of 193 (99.5%) patients.

## 6.3.2.1.6.2. Deviations from study plan

Version 3.0 of the SAP (dated 25 September 2015) included information on additional immunogenicity assessments to be performed in anticipation of a protocol change. However, due to operational reasons, the protocol change was not initiated and as a consequence the additional immunogenicity assessments were not performed.

A summary of the major protocol deviations is presented in the table below.

Table 11: Major protocol deviations (ITT population)

|                                                      | MYL-1401H (N=127)   | EU-Neulasta\" (N=67)   |
|------------------------------------------------------|---------------------|-----------------------|
| Protocol Deviations                                  | m (%)               | m (%)                 |
| Number of Subjects Who Had Major Protocol Deviations | 34 (26.8%)          | 15 (22.4%)            |
| Protocol Deviation Description                       |                     |                       |
| Inclusion/Exclusion Criteria                         | 2 (1.6%)            | 0 (0.0%)              |
| Prohibited Concomitant Medication                    | 1 (0.8%)            | 0 (0.0%)              |
| Additional Protocol Deviations                       | 33 (26.0%)          | 15 (22.4%)            |
| Lab Testing Deviations                               | 15 (11.8%)          | 10 (14.9%)            |
| Special Testing Deviation                            | 11 (8.7%)           | 1 (1.5%)              |
| Other                                                | 6 (4.7%)            | 4 (6.0%)              |
| Dosing-Time Deviation                                | 3 (2.4%)            | 0 (0.0%)              |
| Subject Visit Window Deviation                       | 2 (1.6%)            | 0 (0.0%)              |
| Missed Subject Visit(s)                              | 1 (0.8%)            | 2 (3.0%)              |

Abbreviations: ITT = intent-to-treat; N = mumber of patients; n = number of patients in the sample

## 6.3.2.1.6.3. Baseline data

Out of the 194 (100.0%) patients with newly diagnosed, pathologically confirmed breast cancer 117 (60.3%) had undergone prior breast cancer surgery, 5 (2.6%) had undergone a lumpectomy, 43 (22.2%) had undergone partial or segmented mastectomy, 3 (1.5%) had undergone a simple or total mastectomy, 52 (26.8%) had undergone radical mastectomy, and 21 (10.8%) had undergone modified radical mastectomy.

<div style=\"page-break-after: always\"></div>

Table 12: Patient demographics (ITT Population)

| Parameter                              | MYL-1401H (N=127)   | EU-Neulasta? (N=67)   | Overall (N=194)   |
|----------------------------------------|---------------------|-----------------------|-------------------|
| Age (years)                            |                     |                       |                   |
| Mean  SD                              | 49.5 10.61         | 50.1  9.85           | 49.7 10.33       |
| Median (min, max)                      | 49.0 (25, 79)       | 50.0 (29, 68)         | 50.0 (25, 79)     |
| Age group (years), n (%)               |                     |                       |                   |
| <50                                    | 64 (50.4%)          | 32 (47.8%)            | 96 (49.5%)        |
| 50-65                                  | 56 (44.1%)          | 30 (44.8%)            | 86 (44.3%)        |
| >65                                    | 7 (5.5%)            | 5 (7.5%)              | 12 (6.2%)         |
| Sex, n (%)                             |                     |                       |                   |
| Male                                   | 1 (0.8%)            | 0 (0.0%)              | 1 (0.5%)          |
| Female                                 | 126 (99.2%)         | 67 (100.0%)           | 193 (99.5%)       |
| Ethnicity, n (%)                       |                     |                       |                   |
| Hispanic or Latino                     | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Not Hispanic or Latino                 | 127 (100.0%)        | 67 (100.0%)           | 194 (100.0%)      |
| Race, n (%)                            |                     |                       |                   |
| White                                  | 127 (100.0%)        | 67 (100.0%)           | 194 (100.0%)      |
| Black or African American              | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Asian                                  | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| AmericanIndian/Alaska Native           | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Native Hawaiian/Other Pacific Islander | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |
| Other                                  | 0 (0.0%)            | 0 (0.0%)              | 0 (0.0%)          |

Abbreviations:N=number of patients;n =number of patients in the sample;SD= standard deviation

## 6.3.2.1.6.4. Outcomes and estimation

## Primary Efficacy Endpoint: Duration of Severe Neutropenia: Cycle 1 (PP population)

The mean ( SD) DSN in the MYL-1401H group was 1.2 ( 0.93), the median DSN was 1.0, and the DSN ranged from 0 to 5 days. In the EU-Neulasta group, the mean ( SD) DSN was 1.2 ( 1.10), the median DSN was 1.0, and the DSN ranged from 0 to 4 days. The DSN was 1 day for 51 (40.5%) patients in the MYL-1401H group and 17 (25.4%) patients in the EU-Neulasta group. The DSN was 0 days for 32 (25.4%) patients in the MYL-1401H group and for 24 [35.8%] patients in the EU-Neulasta group. The DSN was 2 days for 25 (27.8%) patients in the MYL-1401H group and for 17 (25.4.%) patients in the EU-Neulasta group (Table 13).

<div style=\"page-break-after: always\"></div>

Table 13: Duration of severe neutropenia in cycle 1 (PP population)

| Parameter                              | MYL-1401H (N=126)                 | EU-Neulasta? (N=67)               |
|----------------------------------------|-----------------------------------|-----------------------------------|
| Durationofsevereneutropenia(days)      | Durationofsevereneutropenia(days) | Durationofsevereneutropenia(days) |
| Mean SD                               | 1.2 0.93                         | 1.2  1.10                        |
| Median, (range)                        | 1.0, (0-5)                        | 1.0, (0-4)                        |
| LS Mean (SE)                           | 1.31 (0.139)                      | 1.30 (0.154)                      |
| LS Mean difference from Neulasta? (SE) | 0.01 (0.148)                      | 0.01 (0.148)                      |
| 95% CIa                                | (-0.285, 0.298)                   | (-0.285, 0.298)                   |
| Duration (days), n (%)                 | Duration (days), n (%)            | Duration (days), n (%)            |
| 0                                      | 32 (25.4%)                        | 24 (35.8%)                        |
| 1                                      | 51 (40.5%)                        | 17 (25.4%)                        |
| 2                                      | 35 (27.8%)                        | 17 (25.4%)                        |
| 3                                      | 7 (5.6%)                          | 8 (11.9%)                         |
| 4                                      | 0 (0.0%)                          | 1 (1.5%)                          |
| 5                                      | 1 (0.8%)                          | 0 (0.0%)                          |

Abbreviations:ANOvA= analysis of variance;CI=confidence interval;N=total number of patients with available data in Cycle 1;n=number ofpatients in the sample;LS Mean=least squaresmean;SD=standard deviation;

SE=standard error

Source: Table 14.2.1.1

a:The95%CIfor thedifferenceinleast squaremeans isbased on theresult of anANOVAmodelwith treatment group, country, and age group as factors. Comparable efficacy was declared if the 95% CI was completely within this range of (-1 day, +1 day)

The 95% CI (-0.285, 0.298) for the difference in least square mean DSN of MYL-1401H and EUNeulasta was found to be within the pre-specified equivalence range of [-1 day, +1 day] based on the ANOVA model with treatment group, country, and age group as factors. Therefore comparable efficacy of MYL-1401H and EU-Neulasta can be declared (null hypothesis that mean DSN in Cycle 1 on MYL1401H differs from mean DSN on EU-Neulasta by 1 day or more can be rejected).

In summary, trial MYL-1401H-3001 met its primary objective.

There were 19 out of 126 (15%) patients in the MYL-1401H group and 13 out of 67 (19.4%) in the EUNeulasta group who tested positive for anti-drug antibody (ADA) and 107 out of 126 (85%) patients in the MYL-1401H group and 54 out of 67 (80.6%) in the EU-Neulasta group who tested positive negative for anti-drug antibody (ADA).

<div style=\"page-break-after: always\"></div>

Table 14 2 : Duration of severe neutropenia in cycle 1 in patients positive for antibody (based on assay with MYL-1401H) (PP population)

| Parameter                                 | MYL-1401H (N=126)   | EU-Neulasta? (N=67)   |
|-------------------------------------------|---------------------|-----------------------|
| Duration of severe neutropenia (days)     |                     |                       |
| n, Mean  SD                              | 19, 1.5 0.77       | 13,0.9 0.95          |
| Median, (range)                           | 2.0,(0-3)           | 1.0, (0-3)            |
| LS Mean (SE)                              | 1.45 (0.311)        | 0.81 (0.314)          |
| LS Mean difference from EU-Neulasta* (SE) | 0.64 (0.289)        | 0.64 (0.289)          |
| 95% CI                                    | (0.039, 1.231)      | (0.039, 1.231)        |
| Duration (days), n (%o)                   |                     |                       |
| 0                                         | 2 (1.6%)            | 5 (7.5%)              |
| 1                                         | 7 (5.6%)            | 5 (7.5%)              |
| 2                                         | 9 (7.1%)            | 2 (3.0%)              |
| 3                                         | 1 (0.8%)            | 1 (1.5%)              |

Abbreviations: ANOVA = analysis of variance ; CI = confidence interval; N = total number of patients with available data in Cycle 1; n = mumber of patients in the sample; LS Mean = least squares mean; SD = standard deviation; SE =standarderror

a: The 95% CI for the difference in LS Mean is based on the result of an ANOVA model with treatment group, country, and age group as factors.

Table 15: Duration of severe neutropenia in Cycle 1 in patients negative for antibody (based on assay with MYL-1401H) (PP population)

| Parameter                                 | MYL-1401H (N=126)   | EU-Neulasta (N=67)   |
|-------------------------------------------|---------------------|----------------------|
| Duration of severe neutropenia (days)     |                     |                      |
| n, Mean  SD                              | 107, 1.10.94       | 54, 1.21.13         |
| Median, (range)                           | 1.0, (0-5)          | 1.0, (0-4)           |
| LS Mean (SE)                              | 1.20 (0.154)        | 1.32 (0.175)         |
| LS Mean difference from EU-Neulasta* (SE) | -0.12 (0.165)       | -0.12 (0.165)        |
| 95% CI                                    | (-0.442,0.210)      | (-0.442,0.210)       |
| Duration (days), n (%o)                   |                     |                      |
| 0                                         | 30 (23.8%)          | 19 (28.4%)           |
| 1                                         | 44 (34.9%)          | 12 (17.9%)           |
| 2                                         | 26 (20.6%)          | 15 (22.4%)           |
| 3                                         | 6 (4.8%)            | 7 (10.4%)            |
| 4                                         | 0 (0.0%)            | 1 (1.5%)             |
| 5                                         | 1 (0.8%)            | 0 (0.0%)             |

Abbreviations: ANOVA = analysis of variance ; CI = confidence inteival; N = total number of patients wifh available data in Cycle 1; n = number of patients in the sample; LS Mean = least squares mean; SD = standard deviation; SE =standard error

a: The 95% CI for the difference in LS Mean is based on the result of an ANOVA model with treatment group, country, and age group as factors.

<div style=\"page-break-after: always\"></div>

## Secondary (efficacy) endpoints

There were small numerical differences for secondary efficacy endpoints (depths of nadir, frequency of severe neutropenia, frequency of febrile neutropenia) not precluding a conclusion of biosimilarity.

Table 16: Frequency, depth, and time of neutropenia in cycle 1 (PP population)

| Parameter                                                | MYL-1401H (N=126)                                        | EU-Neulasta? (N=67)                                      |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* |
| Grade 3 or 4 neutropenia                                 | 114 (90.5%)                                              | 55 (82.1%)                                               |
| Grade 4 neutropenia                                      | 94 (74.6%)                                               | 43 (64.2%)                                               |
| Grade 3 neutropenia                                      | 20 (15.9%)                                               | 12 (17.9%)                                               |
| ANC nadir (10%/L)                                        | ANC nadir (10%/L)                                        | ANC nadir (10%/L)                                        |
| Mean (SD)                                                | 0.40 ( 0.47)                                            | 0.78 ( 1.43)                                            |
| Median (range)                                           | 0.21 (0.0-2.5)                                           | 0.27 (0.0-6.7)                                           |
| ANC-time to nadir (days)                                 | ANC-time to nadir (days)                                 | ANC-time to nadir (days)                                 |
| Mean (SD)                                                | 6.2 ( 0.98)                                             | 6.3 (1.57)                                              |
| Median (range)                                           | 6.0 (0-12)                                               | 6.0 (1-14)                                               |
| Post-nadir ANC recovery, n (%o)                          | Post-nadir ANC recovery, n (%o)                          | Post-nadir ANC recovery, n (%o)                          |
| ON                                                       | 0 (0.0%)                                                 | 0 (0.0%)                                                 |
| Yes                                                      | 125 (99.2%)                                              | 67 (100.0%)                                              |
| Not evaluable                                            | 1 (0.8%)                                                 | 0 (0.0%)                                                 |
| Time to post-iadir ANC recovery                          | Time to post-iadir ANC recovery                          | Time to post-iadir ANC recovery                          |
| n, Mean (SD)                                             | 125, 1.9 ( 0.85)                                        | 67, 1.7 ( 0.91)                                         |
| Median (range)                                           | 2.0 (0-4)                                                | 2.0 (0-3)                                                |
| Time (day), n (%)                                        | Time (day), n (%)                                        | Time (day), n (%)                                        |
| 0                                                        | 6 (4.8%)                                                 | 9 (13.4%)                                                |
| 1                                                       | 38 (30.4%)                                               | 24 (35.8%)                                               |
|                                                          | 101 (80.8%)                                              | 56 (83.6%)                                               |
| 3                                                        | 121 (96.8%)                                              | 67 (100.0%)                                              |
| 4                                                       | 125 (100.0%)                                             | 67 (100.0%)                                              |

Abbreviations: ANC = absolute neutrophil count; L = liter; N = total number of patients with available data in

Cycle 1; n = mumber of patients in the sample; PP = per protocol; SD = standard deviation

<div style=\"page-break-after: always\"></div>

Table 17 3 : Frequency of neutropenia by cycle (ITT population)

| Parameter Cycle                                          | MYL-1401H (N=127)                                        | EU-Neulasta (N=67)                                       |
|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* | Frequency of the worst Grade 3 or 4 neutropenia, n (%6)* |
| Grade 3 or 4 neutropenia                                 | 120 (94.5%)                                              | 56 (83.6%)                                               |
| Grade 4 neutropenia                                      | 103 (81.1%)                                              | 49 (73.1%)                                               |
| Grade 3 neutropenia                                      | 17 (13.4%)                                               | 7 (10.4%)                                                |
| Cycle 2                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 53 (42.4%)                                               | 29 (43.3%)                                               |
| Grade 4 neutropenia                                      | 19 (15.2%)                                               | 15 (22.4%)                                               |
| Grade 3 neutropenia                                      | 34 (27.2%)                                               | 14 (20.9%)                                               |
| Cycle 3                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 51 (41.1%)                                               | 28 (41.8%)                                               |
| Grade 4 neutropemia                                      | 34 (27.4%)                                               | 16 (23.9%)                                               |
| Grade 3 neutropenia                                      | 17 (13.7%)                                               | 12 (17.9%)                                               |
| Cycle 4                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropemia                                 | 66 (53.2%)                                               | 30 (44.8%)                                               |
| Grade 4 neutropenia                                      | 30 (24.2%)                                               | 18 (23.9%)                                               |
| Grade 3 neutropenia                                      | 36 (29.0%)                                               | 12 (17.9%)                                               |
| Cycle 5                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 60 (48.8%)                                               | 26 (39.4%)                                               |
| Grade 4 neutropenia                                      | 38 (30.9%)                                               | 13 (19.7%)                                               |
| Grade 3 neutropenia                                      | 22 (17.9%)                                               | 13 (19.7%)                                               |
| Cycle 6                                                  |                                                          |                                                          |
| Grade 3 or 4 neutropenia                                 | 59 (49.2%)                                               | 28 (42.4%)                                               |
| Grade 4 neutropenia                                      | 34 (28.3%)                                               | 20 (30.3%)                                               |
| Grade 3 neutropenia                                      | 25 (20.8%)                                               | 8 (12.1%)                                                |

Abbreviations: n = number of patients in the sample; N = total number of patients with available data

Source: Table 14.2.3.2

*If a patient experienced more than 1 grade of neutropenia, only the highest grade was counted.

Table 18: Rate of febrile neutropenia (cycle 1) (ITT population)

| Parameter                            | M11L-1401H (N=127)   | EU-Neulasta (N=67)   |   P-value |
|--------------------------------------|----------------------|----------------------|-----------|
| Rate of febrile neutropenia, n ( (%) | 5 (3.9%)             | 1 (1.5%)             |      0.35 |

Febrile neutropemia is defined as febrile neutropenia reported as an AE.

Abbreviations: AE = adverse event; ITT =intent to treat; N= total number of patients with available data in Cycle 1; n = mumber of patients in the sample

<div style=\"page-break-after: always\"></div>

Table 19: Rate of febrile neutropenia by cycle (ITT population)

|                                            | MYL-1401H (N=127)   | EU-Neulasta (N=67)   |
|--------------------------------------------|---------------------|----------------------|
| Parameter                                  | n (%)               | n (%)                |
| Rate of febrile neutropenia for all cycles | 7 (5.5%)            | 1 (1.5%)             |
| Rate of febrile neutropenia in Cycle 1     | 5 (3.5%)            | 1 (1.5%)             |
| Rate of febrile neutropenmia in Cycle 2    | 1 (0.8%)            | 0 (0.0%)             |
| Rate of febrile neutropemia in Cycle 3     | 1 (0.8%)            | 0 (0.0%)             |
| Rate of febrile neutropenia in Cycle 4     | 0 (0.0%)            | 0 (0.0%)             |
| Rate of febrile neutropenia in Cycle 5     | 0 (0.0%)            | 0 (0.0%)             |
| Rate of febrile neutropenmia in Cycle 6    | 0 (0.0%)            | 0 (0.0%)             |

Febrile neutropenia is defined as febrile neutropenia reported as an AE.

Abbreviations: AE = adverse event; ITT = intent to treat; n = mumber of patients in the sample

## 6.3.2.1.6.5. Ancillary analyses

N/A

## 6.3.3. Clinical studies in special populations

The applicant did not submit clinical studies in special populations (see clinical discussion).

## 6.3.4. In vitro biomarker test for patient selection for efficacy

N/A

## 6.3.5. Supportive study(ies)

N/A

## 6.3.6. Analysis performed across trials (pooled analyses and metaanalysis)

N/A

## 6.3.7. Overall discussion and conclusions on clinical efficacy

## 6.3.7.1. Discussion

The applicant submitted the results of a parallel-group, active controlled, blinded trial to show equivalence in terms of DSN. The study design was in accordance with scientific recommendations as outlined in the respective EMA guideline currently in place.

There are minor criticisms on trial 3001 such as administering TAC to patients in neo-adjuvant intent, and not stratifying TAC for adjuvant/neo-adjuvant. These are, however, minor design and conduct issues which have, in essence, no effect on the biosimilar conclusion.

The primary analysis, as well as the sensitivity analyses, of the primary endpoint are robust and allow the conclusion which read:

The primary objective of the study was met, where the median DSN was 1.0 day (range 0-5) and EUNeulasta was 1.0 (0.4), the LS mean difference from Neulasta was 0.01 (95%CI -0.285, 0.298),

<div style=\"page-break-after: always\"></div>

determined by the ANOVA analysis (with treatment group, country, and age group as factors for the difference in least square mean DSNs of MYL-1401H and EU-Neulasta). The results were found to be within the pre-specified equivalence range of [-1 day, +1 day]. In fact, the 95% CIs were very narrow allowing a firm conclusion of similar efficacy. These results show that there are no significant differences between the two products in terms of DSN, supporting the claim for biosimilarity.

There were small numerical differences for secondary efficacy endpoints (depths of nadir, frequency of severe neutropenia, frequency of febrile neutropenia) not precluding a conclusion of biosimilarity. However, these were not considered clinically relevant. Secondary endpoints and the result of the frequency of neutropenia for cycle 2 to 6 lend overall support to the therapeutic equivalence between Vivlipeg and Neulasta.

## 6.3.7.2. Conclusions on the clinical efficacy

The clinical data in the trial MYL-1401H-3001 in patients undergoing cytotoxic chemotherapy has shown comparable efficacy between Vivlipeg and Neulasta in reducing the duration of severe neutropenia. Hence, Vivlipeg and Neulasta EU-sourced offer therapeutic equivalence which supports the claim for biosimilarity.

## 6.4. Clinical safety

For the purpose of this document, the following definitions apply:

'Adverse event - AE' means any untoward medical occurrence in a subject to whom a medicinal product is administered and which does not necessarily have a causal relationship with this treatment.

'Serious adverse event - SAE' means any untoward medical occurrence that at any dose requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, results in a congenital anomaly or birth defect, is life-threatening, or results in death. The definition (in line with ICH E2A) includes important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the definition above.

'Adverse Drug Reaction - ADR' means any untoward and unintended response to a medicinal product related to any dose administered, for which, after a thorough assessment, a causal relationship between the medicinal product and the adverse event is at least a reasonable possibility, based for example, on their comparative incidence in clinical trials, or findings from epidemiological studies and/or on an evaluation of causality from individual case reports.

## 6.4.1. Safety data collection

The applicant conducted 3 clinical studies that have evaluated the comparability of safety between MYL-1401H and Neulasta: 2 studies in healthy subjects (MYL-1401H-1001 and MYL-1401H-1002) and 1 comparative safety and efficacy study in patients with Stage II/III invasive breast cancer (MYL1401H-3001).

Due to differences in the study dose, study design, and populations, the safety data from the 3 studies (MYL-1401H-1001, MYL-1401H-1002, and MYL-1401H-3001) have not been integrated.

The clinical trial specifically dedicated to immunogenicity is trial MYL-1401H-1002. However, a thorough assessment of immunogenicity was conducted across the 3 clinical studies (see below).

<div style=\"page-break-after: always\"></div>

## 6.4.2. Patient exposure

A total of 232 healthy subjects and 127 patients diagnosed with breast cancer have received at least 1 dose of MYL-1401H.

In 3-way crossover Study MYL-1401H-1001, 216 healthy male and female subjects received at least one 2-mg SC injection of pegfilgrastim and 198 subjects received the planned 3 doses of pegfilgrastim: 207 subjects received at least 1 dose of MYL-1401H (test product), 208 subjects received at least 1 dose of EU-Neulasta and 207 subjects received at least 1 dose of US-Neulasta.

In Study MYL-1401H-1002, 25 healthy male and female subjects received at least one 6-mg SC injection of MYL-1401H (test product) and 25 healthy male and female subjects received at least one 6-mg SC injection of US-Neulasta. Two 6-mg SC injections were received by 23 subjects in the MYL1401H group and 21 subjects in the US-Neulasta group.

In Study MYL-1401H-3001, 127 patients received at least one 6-mg SC injection of MYL-1401H (test product) and 67 patients received at least one 6-mg SC injection of EU-Neulasta. One hundred twenty (94.5%) patients in the MYL-1401H group and 66 (98.5%) patients received all 6 doses of study drug. During each cycle, the majority of patients received their study drug on Day 2 of the cycle as scheduled.

## 6.4.3. Adverse events

## Study MYL-1401H-1001

In Study MYL-1401H-1001, safety and tolerability were evaluated after the single 2-mg sc injection by evaluating all AEs, physical examinations, vital signs, ECGs, clinical laboratory, local tolerance, and immunogenicity (early development of ADA).

There were 1129 TEAEs reported by 200 (93%) subjects that were considered related to pegfilgrastim treatment with 177 (86%) subjects who received MYL-1401H, 182 (88%) subjects who received EUNeulasta, and 181 (87%) subjects who received US-Neulasta (Table 20).

Table 20: Overview of treatment-emergent adverse events during the study (1001)

|                                                      | MYL-1401H (N=207) n (%)   | EU-Neulasta (N=208) n (%)   | US-Neulasta (N=207) n (%)   |
|------------------------------------------------------|---------------------------|-----------------------------|-----------------------------|
| Number of subjects with at least 1 TEAE              | 177 (86)                  | 182 (88)                    | 181 (87)                    |
| Number of subjects with at least 1 related TEAE      | 156 (75)                  | 165 (79)                    | 157 (76)                    |
| Number of subjects with at least 1 TEAE by severity: |                           |                             |                             |
| Grade 1 (mild) severity                              | 158 (76)                  | 172 (83)                    | 166 (80)                    |
| Grade 2 (moderate) severity                          | 86 (42)                   | 92 (44)                     | 84 (41)                     |
| Grade 3 (severe) severity                            | 0 (0)                     | 0 (0)                       | 1 (>0)                      |
| Number of subjects withdrawn due to (S)AEs:          | 0 (0)                     | 2 (1)                       | 1 (>0)                      |
| SAE                                                  | 0 (0)                     | 0 (0)                       | 1 (>0)                      |
| AE                                                   | 0 (0)                     | 2 (1)                       | 0 (0)                       |

Abbreviations: AE = adverse event; EU = European Union; SAE = serious adverse event; TEAE = treatment-emergent adverse event; US = United States

In MYL-1401H-1001, the most commonly reported TEAE by preferred term (PT) were back pain (81% of the  subjects),  headache  (63%  of  the  subjects),  pain  in  extremity  (36%  of  the  subjects)  and nasopharyngitis (22% of the subjects). There were no relevant differences in the frequencies of TEAEs

<div style=\"page-break-after: always\"></div>

or  percentages  of  subjects  reporting  TEAEs  among  MYL-1401H  and  the  reference  treatments  (EUNeulasta and US-Neulasta).

## Study MYL-1401H-1002

A summary of all Treatment-Emergent Adverse Events is provided in Table 21 below.

Table 21: Overview of treatment-emergent adverse events during the study (1002)

|                                                      | MYL-1401H (N=25) n (%)   | US-Neulasta (N=25) n (%)   |
|------------------------------------------------------|--------------------------|----------------------------|
| Number of subjects with at least 1 TEAE              | 24 (96.0%)               | 25 (100.0%)                |
| Number of subjectswith at leastl related TEAE        | 24 (96.0%)               | 25 (100.0%)                |
| Number of subjects with at least 1 TEAE by severity: |                          |                            |
| Grade 1 (mild)                                       | 23 (92.0%)               | 23 (92.0%)                 |
| Grade 2 (moderate)                                   | 19 (76.0%)               | 22 (88.0%)                 |
| Grade 3 (severe)                                     | 0 (0.0%)                 | 1 (4.0%)                   |
| Number of subjects withdrawn due to (S)AEs:          | 2 (8.0%)                 | 4 (16.0%)                  |
| SAE                                                  | 0 (0.0%)                 | 0 (0.0%)                   |
| AE                                                   | 2 (8.0%)                 | 4 (16.0%)                  |

AE = adverse event; N = the # of subjects exposed to the treatment; n = the # of subjects that experienced the adverse event; SAE = serious adverse event; TEAE = treatment-emergent adverse event; % is calculated as (n/N)*100

There were 376 TEAEs reported by 49 (98%) subjects: 188 TEAEs by 24 (96.0%) subjects who received MYL-1401H and 188 TEAEs by 25 (100.0%) subjects who received the reference product USNeulasta.

Generally, most TEAEs reported during the study were consistent with the clinical data of pegfilgrastim (Neulasta). No serious AEs (SAEs) or unexpected TEAEs were reported.

The number of TEAEs and percentage of subjects reporting TEAEs was comparable between MYL1401H and the reference product US-Neulasta: 188 TEAEs reported by 24 (96.0%) subjects and 188 TEAEs reported by 25 (100.0%) subjects, respectively. The most frequently reported TEAEs by system organ class (SOC) (i.e., reported by &gt;50% of the subjects) were musculoskeletal and connective tissue disorders (by 90.0% of the subjects), nervous system disorders (72.0%), and general disorders and administration site conditions (60.0%). The most frequently reported preferred terms (PTs) (i.e., reported by 20% of the subjects) were back pain (80.0%), headache (70.0%), injection site pain (30.0%), fatigue (26.0%), myalgia (24.0%), non-cardiac chest pain (24.0%), pain in extremity (20.0%), and abdominal pain (20.0%). There were no relevant differences in the frequency of TEAEs or percentage of subjects reporting TEAEs between MYL-1401H and US-Neulasta.

## Study MYL-1401H-3001

In Study MYL-1401H-3001, 806 TEAEs were reported in 114 (89.8%) patients in the MYL-1401H group and 414 TEAEs were reported in 58 (86.6%) patients in the EU-Neulasta group. Among the patients with TEAEs, the majority had TEAEs that resolved during the study (104 [81.9%] patients in the MYL1401H group and 47 [70.1%] patients in the EU-Neulasta group). An overview of TEAEs in Study MYL1401H-3001 is provided in Table 22.

<div style=\"page-break-after: always\"></div>

Table 224: Overview of treatment-emergent adverse events during the study (3001)

|                                                               | MYL-1401H (N=127) n (%)   | US-Neulasta (N=67) n (%)   |
|---------------------------------------------------------------|---------------------------|----------------------------|
| Number of TEAEs                                               | 806                       | 414                        |
| Number of patients with at least 1 TEAE                       | 114 (89.8)                | 58 (86.6)                  |
| Number of patients with at least 1 pegfilgrastim-related TEAE | 57 (44.9)                 | 24 (35.8)                  |
| Number of patients with at least 1 TEAE by severity:          |                           |                            |
| Grade 1 (mild) severity                                       | 34 (26.8)                 | 15 (22.4)                  |
| Grade2(moderate)severity                                      | 56 (44.1)                 | 35 (52.2)                  |
| Grade 3 (severe) severity                                     | 24 (18.9)                 | 8 (11.9)                   |
| Number of patients with SAE(s):                               |                           |                            |
| Not related                                                   | 8 (6.3)                   | 1 (1.5)                    |
| Related                                                       | 0                         | 0                          |
| Number of patients withdrawn due to (S)AEs:                   |                           |                            |
| Grade 1 (mild) severity                                       | 0                         | 0                          |
| Grade2(moderate)severity                                      | 3 (2.4)                   | 0                          |
| Grade 3 (severe) severity                                     | 1 (0.8)                   | 0                          |

Abbreviations: AE = adverse event; SAE = serious adverse event; TEAE = treatment-emergent adverse event;

US =United States

The most commonly reported TEAE by preferred term was alopecia reported by 76 (59.8%) patients in the MYL-1401H group and 36 (53.7%) patients in the EU-Neulasta group. Of patients with this TEAE, most had CTCAE Grade 1 events (36 [28.3%] patients in the MYL-1401H group and 14 [20.9%] patients in the EU-Neulasta group) and Grade 2 events (36 [28.3%] patients in the MYL-1401H group and 22 [32.8%] patients in the EU-Neulasta group). The events of alopecia were not considered related to the study drug by the investigator.

The TEAE of bone pain was reported for 51 (40.2%) patients in the MYL-1401H group and 24 (35.8%) patients in the EU-Neulasta group. Of the patients with this TEAE, most had CTCAE Grade 1 (21 [16.5%] patients in the MYL-1401H group and 10 [14.9%] patients in the EU-Neulasta group) and Grade 2 (26 [20.5%] patients in the MYL-1401H group and 13 [19.4%] patients in the EU-Neulasta group). Fifty (39.4%) patients in the MYL-1401H group and 23 (34.3%) patients in the EU-Neulasta group) had treatment-related TEAEs of bone pain. Bone pain was managed by simple analgesics, and no patients discontinued from the study as a result of their bone pain. The majority of the events of bone pain were reported in Cycle 1 (44 [34.6%] in the MYL-1401H group and 17 [25.4%] in the EUNeulasta group). However, a higher rate of use of naproxen was reported during Cycle 1 in the EUNeulasta group, 19 (28.4%) patients compared to 25 (19.8%) in the MYL-1401H group. Notably, the Brief Pain Inventory questionnaire, a sensitive and relevant measure of the intensity and interference of pain in the patient's life, was similar between the treatment groups.

There were 8 patients with thrombocytosis in the MYL-1401H group that were Grade 1 or 2 in severity and resolved without any intervention. The actual laboratory values of platelets were similar between the treatment groups (approximately 65 [51.2%] patients in the MYL-1401H group had at least 1 episode of elevated platelet count &gt;450 compared with 35 [52.2%] in the EU-Neulasta group and about half of these were single isolated episodes in both the groups). At the end-of-study visit, the mean and median platelets and the change from baseline in platelet counts were similar between the treatment groups. Additionally, the AE reporting of thrombocytosis appeared to be subjective, with only 3 of 24 sites reporting all the 8 events of thrombocytosis in the MYL-1401H group.

## 6.4.4. Adverse event of special interest, serious adverse events and deaths, other significant events

## Study MYL-1401H-1001

In Study MYL-1401H-1001, 1 serious AE (SAE) of appendicitis in the US-Neulasta group occurred and resulted in subject withdrawal. The SAE was not considered to be related to pegfilgrastim.

<div style=\"page-break-after: always\"></div>

## Study MYL-1401H-1002

No SAEs were reported in Study MYL-1401H-1002.

## Study MYL-1401H-3001

In Study MYL-1401H-3001, SAEs were infrequent. A total of 9 (4.6%) patients in the safety population had at least 1 SAE (8 [6.3%] patients in the MYL-1401H group and 1 [1.5%] patients in the EUNeulasta group. There were no SAEs considered by the investigator to be related to study drug.

Six of 127 (4.7%) patients had FN in the MYL-1401H group and 1 of 67 (1.5%) patients had FN in the EU-Neulasta group, which were considered to be SAEs. All the events of FN lasted less than 5 days, no documented infections nor sepsis events were observed during the events of FN, and all the FN events resolved without the use of rescue therapy. Of 7 patients with FN considered SAEs, only 3 patients met the ESMO definition for FN while 4 other patients had insufficient data. However, these patients were conservatively included under the category of FN.

There was 1 patient with an SAE of erysipelas and 1 patient with SAEs of hypokalaemia and anaemia in the MYL-1401H group, all of which were deemed resolved at the time of data analysis. All SAEs were deemed unrelated to the study drug by the investigator.

All SAEs of FN were deemed related to the chemotherapy and unrelated to treatment with MYL-1401H or EU-Neulasta by the investigator. There was no significant difference in the rate of FN between the treatment groups (p=0.35) based on a chi-square test comparing the proportion of patients with FN between the treatment groups. Given the 2:1 randomisation, small sample size, and frequency of ANC assessments based on safety considerations, it is believed that these minor differences are incidental findings. All events of FN lasted less than 5 days, no documented infections or sepsis events were observed during the events of FN, and all FN events resolved without the use of rescue therapy.

No deaths occurred during any of the MYL-1401H clinical studies.

## 6.4.5. Immunological events

A thorough assessment of immunogenicity was conducted across the 3 clinical studies. The clinical program included Study MYL-1401H-1001 and Study MYL-1401H-1002, which were conducted in normal healthy volunteers, and Study MYL-1401H-3001, which was conducted in patients with breast cancer who were receiving chemotherapy. Serum samples were analysed for the presence of ADA against MYL-1401H or Neulasta (either EU-Neulasta and/or US-Neulasta). Samples that were positive in the screening assay were further evaluated in a confirmatory assay. The samples confirmed as ADApositive were titrated to quantify the ADA response and were further evaluated for moiety characterisation to determine if the antibodies were specifically directed against the PEG and/or the filgrastim moiety of the molecule.

The immunogenicity assessment in the pivotal PK/PD Study MYL-1401H-1001 was limited. It evaluated a 2-mg dose, which is sub-therapeutic, and had a 3-way crossover design. Since subjects crossed over to other treatments, immunogenicity data from baseline through Day 29 in Period 1 (i.e., Period 2 pre-dose) are the most relevant for discussion, while data from Period 2 and Period 3 are potentially confounded.

A 7% (16 of 216 subjects overall) baseline frequency of ADA+ subjects is notable, as well as a small imbalance (9 (4%) subjects prior to administration of MYL-1401H, 4 (2%) subjects prior to EUNeulasta and 3 (1%) subjects prior to US-Neulasta). Most of these baseline ADAs were directed against PEG, or PEG and filgrastim, but not filgrastim alone. A volunteer having ADAs directed against neither the PEG nor the filgrastim portion of the molecule seems to be a false positive ADA result.

<div style=\"page-break-after: always\"></div>

Prior to dosing on Day 1 of Period 2 (Table 23), which was Day 29 of Period 1 and the most relevant for immunogenicity assessment, 27 of the 208 (13%) subjects had positive ADA results at this time point with median ADA titre of 4 for each of the 3 treatments. Of the 27 subjects with confirmed positive results at pre dose in Period 2, 10 subjects had pre-existing ADAs at baseline and the other 17 (8%) subjects developed ADAs after the first dose of study drug (5 subjects after MYL-1401H, 5 subjects after EU-Neulasta, and 7 subjects after US-Neulasta). For these 17 subjects, the increased ADAs were considered to be treatment-induced positive ADA results. Thus, the incidence of treatment induced ADA positivity was similar across all the 3 dosing groups (7.2-9.7%) in Period 1.

Table 23: Summary of subjects with treatment-induced anti-drug antibodies at pre-dose in period 2 (1001)

|                      | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   | ADA Results at Predose (Day 1) in Period 2, by Administration of the First Dose   |
|----------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| First doseinPeriod 1 | Total confirmed positive for ADAs n                                               | Treatment-induced ADAsb n (%)                                                     | treatment- induced positivesa                                                     | Mean titer of Predose positives with >3-fold ADA titer increase n (%)             |
| MYL-1401H (N=69)a    | 11                                                                                | 5 (7.2)                                                                           | 4                                                                                 | 1 (1.4)                                                                           |
| EU-Neulasta? (N=67)a | 7                                                                                 | 5 (7.5)                                                                           | 2                                                                                 | 1 (1.5)                                                                           |
| US-Neulasta? (N=72)a | 9                                                                                 | 7 (9.7)                                                                           | 9                                                                                 | 1 (1.4)                                                                           |
| Total (N=208)        | 27                                                                                | 17 (8.2)                                                                          |                                                                                   | 3 (1.4)                                                                           |

Abbreviations: ADA = anti-drug antibody; EU = European Union; N = number of patients; n = number of patients in the sample; US = United States

a The number of subjects shown and used for the calculation of percentages in this table are the number of subjects with data available at Period 2 predose (Study Day 29).

- Subjects who were confirmed positive ADA prior to administration of the first dose in Period 1 were excluded

Prior to dosing in Period 3, 13 of the 198 (6%) subjects continued to have positive ADA results. The median ADA titres were comparable across treatments (median titre: 2, 4, and 4 for MYL-1401H, EUNeulasta and US-Neulasta, respectively).

At follow up, a total of 14 of the 213 (6%) subjects were found positive for ADA that included 6 subjects with ADAs present prior to the first dose of study drug and 8 subjects that were considered to have treatment-induced positive ADA results (including 4, 1, and 3 subject[s] who received MYL1401H, EU-Neulasta, or US-Neulasta as first dose of study drug, respectively). All ADA titres were &lt;30 at follow up.

The follow-up result make clear why a cross-over design is all but optimal for testing immunogenicity: The treatments actually consisted of 6 different sequences of 3 different products.

Samples that were ADA positive were further assessed for NAb. A total of 72 subjects with ADA positive samples were analysed for NAbs (Table 24).

The term '72 subjects with ADA positive samples' gives approximately the same proportion of 'immunogenicity' as in trial 1002 the wording 'ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received USNeulasta'. 72/216 (see above) is 33.3%. Thus, this 'phenomenon' is not dose related.

<div style=\"page-break-after: always\"></div>

Table 24: Summary of neutralizing antibodies by visit (1001)

| Visit           | NAb Assay       | MYL-1401H (N=72) n (%)   | EU-Neulasta (N=72) n(%)   | US-Neulasta (N=72) n (%)   | Total (N=216) n (%)   |
|-----------------|-----------------|--------------------------|---------------------------|----------------------------|-----------------------|
| Period1Predose  |                 |                          |                           |                            |                       |
| (Day 1)         | Total#ofsamples | 72                       | 72                        | 72                         | 216                   |
|                 | Negative        | 5 (6.9)                  | 3 (4.2)                   | 3 ( 4.2)                   | 11 ( 5.1)             |
|                 | Positive        | 4 (5.6)                  | 1 (1.4)                   | 0 (0.0)                    | 5 (2.3)               |
|                 | Not Reportable  | 0 (0.0)                  | 0 (0.0)                   | 0(0.0)                     | 0 (0.0)               |
|                 | No Assay        | 63 (87.5)                | 68 ( 94.4)                | 69 (95.8)                  | 200 (92.6)            |
| Period 1 Day 8  | Total#ofsamples | 72                       | 72                        | 72                         | 216                   |
|                 | Negative        | 18 (25.0)                | 16 (22.2)                 | 21 ( 29.2)                 | 55 (25.5)             |
|                 | Positive        | 3 (4.2)                  | 3 (4.2)                   | 3 ( 4.2)                   | 9 ( 4.2)              |
|                 | Not Reportable  | 0 (0.0)                  | 0 (0.0)                   | 0 (0.0)                    | 0 (0.0)               |
|                 | No Assay        | 51 ( 70.8)               | 53 (73.6)                 | 48 (66.7)                  | 152 ( 70.4)           |
| Period 2Predose |                 |                          |                           |                            |                       |
| (Day 1)         | Total#ofsamples | 69                       | 67                        | 72                         | 208                   |
|                 | Negative        | 7(9.7)                   | 4 (5.6)                   | 9 ( 12.5)                  | 20 (9.3)              |
|                 | Positive        | 4 (5.6)                  | 2 (2.8)                   | 0 (0.0)                    | 6 (2.8)               |
|                 | Not Reportable  | 0 (0.0)                  | 1 (1.4)                   | 0 (0.0)                    | 1(0.5)                |
|                 | No Assay        | 58 (80.6)                | 60 (83.3)                 | 63 (87.5)                  | 181 (83.8)            |

- Abbreviations: ADA = anti-drug antibody; EU =European Union; N = number of patients; n = number of patients in the sample; NAb = neutralizing antibodies; US = United States

Note: Day 8 of Period 1 immunogenicity samples consist of pooled pharmacokinetic samples that were collected on Day8 and Day9 of Period 1. There are 2 subjects with samples collected on Day 7 and Day8 due to missing visit on Day 9.

Study MYL-1401H-1002 was specifically designed to assess immunogenicity and evaluated a 6-mg repeated dose in normal healthy volunteers. It also evaluated both an early (IgM) and late (IgG) immunogenic response in a controlled setting.

Samples for determination of ADA were taken each period on Day -1, on Days 8, 15, and 22, and at follow-up.

Based on the SAF set, the confirmatory assay for ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received USNeulasta. There was no time-dependent increase in ADA titre following dosing of either MYL-1401H or US-Neulasta. Two subjects (MYL-1401H) and one subject (US-Neulasta) had a positive ADA result before first dosing on Day -1 of the first period.

Two subjects (MYL-1401H) continued to have positive ADA results at all time points measured, including follow-up, whereas one Subject (US-Neulasta) had no positive ADA results after dosing. Positive ADA results at follow-up were seen for 4 subjects who received MYL-1401H and 2 subjects who received US-Neulasta. A maximum titre of 30 was measured once for one subject (on Day 15, MYL-1401H) and once for one subject (at follow-up, US-Neulasta).

Based on the per-protocol (PP) set (subjects who received both doses of study drug), at the majority of the 9 time points measured, subjects who received MYL-1401H had slightly more positive ADA results than subjects who received US-Neulasta.

All samples confirmed as positive for ADA (mainly against PEG) were further analysed for NAb using a validated cell-based assay.

Based on the PP set (subjects who received both doses of study drug), no positive NAb results were seen for any of the subjects. Based on the SAF set however, positive NAb results were seen for one subject (MYL-1401H) and one subject (US-Neulasta).

One subject (in the MYL-1401H arm) had positive ADA results at 4 time points in Period 1 (pre-dose [Day -1], Day 8 and Day 15, and at follow up after Period 1). At the first 3 of these time points (with ADA titres of 7 [pre-dose], 4, and 30), the NAb results were also positive. This subject was withdrawn

<div style=\"page-break-after: always\"></div>

after the first period due to a treatment-emergent adverse event (TEAE) of headache and was not included in the PP set; therefore, the subject had a follow-up visit after Period 1. At this follow-up visit, the subject was not positive for NAb.

Another subject had a treatment-emergent, positive ADA result at 1 time point (with an ADA titre of 2 at Period 1, Day 8) at which time the NAb results were also positive. The subject did not have positive ADA prior to study start and therefore, ADA and NAb positivity was treatment-emergent. This subject was also withdrawn from the study after Period 1 due to a TEAE of headache and therefore was not included in the PP set.

<!-- image -->

ADA = anti-drug antibody

Figure 7: Percentages of subjects with positive ADA versus time by treatment (PP set)

##  Relationship Between Immunogenicity and Pharmacodynamic Results

For the 2 subjects that had a maximum ADA titre of 30, one subject (Day 15, MYL-1401H) and other subject (follow-up, US-Neulasta), the effect of pegfilgrastim treatment on ANC levels appeared not to be different from the subjects that had no positive ADA counts or positive ADA counts with lower titres. Based on this it appeared that the formation of ADA had no effect on the PD effects of pegfilgrastim.

Finally, immunogenicity was also evaluated in the relevant patient population within Study MYL-1401H3001, in which patients with breast cancer received multiple doses of MYL-1401H or Neulasta in addition to their chemotherapeutic dosing regimen. Thus, the overall immunogenicity assessment includes evaluation of early and late immune response, response after multiple dosing in healthy volunteers as well as in patients, and response after low and therapeutic doses of MYL-1401H and Neulasta.

Table 25 and Table 26 summarise the immunogenicity data at the sample and subject levels integrated across the 3 studies.

The proportions of ADA-positive samples were similar in MYL-1401H and EU-Neulasta groups (8.38.7%) and slightly higher (12.7%) in US-Neulasta group. At a subject level, 22.3% and 23.7% of subjects were positive at least once in MYL-1401H and EU-Neulasta arm respectively, while the proportion was slightly higher at 33% in the US-Neulasta arm. Data from US-Neulasta is only from healthy subjects and it could have contributed to higher proportion of ADA positive response in that arm. Both at subject and sample level, most of the ADA positivity was against the PEG moiety of the molecule across the 3 groups.

<div style=\"page-break-after: always\"></div>

Table 25: Integrated summary of all immunogenicity results by sample (1001, 1002, 3001, ITT population)

| Parameter                          | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|------------------------------------|-------------|---------------|---------------|
| Total # of Samples                 | 1050        | 545           | 417           |
| Positive ADA samples at least once | 91 (8.7)    | 45 (8.3)      | 53 (12.7)     |
| PEG+ only at least once            | 46 (4.4)    | 31 (5.7)      | 33 (7.9)      |
| GCSF+ only at least once           | 13 (1.2)    | 1 (0.2)       | 0 (0.0)       |
| PEG+ & GCSF+ at least once         | 23 (2.2)    | 10 (1.8)      | 16 (3.8)      |
| PEG- & GCSF- at least once         | 9 (0.9)     | 3 (0.6)       | 4 (1.0)       |
| NAb+ at least once                 | 12 (1.1)    | 1 (0.2)       | 1 (0.2)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

Table 26 5 : Integrated summary of all immunogenicity results by subject (1001, 1002, 3001, ITT population)

| Parameter                          | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|------------------------------------|-------------|---------------|---------------|
| Total # of Subjects                | 224         | 139           | 97            |
| Positive ADA samples at least once | 50 (22.3)   | 33 (23.7)     | 32 (33.0)     |
| PEG+ only at least once            | 29 (12.9)   | 27 (19.4)     | 23 (23.7)     |
| GCSF+ only at least once           | 3 (1.3)     | 1 (0.7)       | 0 (0.0)       |
| PEG+ & GCSF+ atleast once          | 17 (7.6)    | 7 (5.0)       | 11 (11.3)     |
| PEG-& GCSF- at least once          | 8 (3.6)     | 3 (2.2)       | 4 (4.1)       |
| NAb+ at least once                 | 6 (2.7)     | 1 (0.7)       | 1 (1.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

It is known that healthy subjects and patients are exposed to PEG-containing chemicals in the environment, and that anyone has a potential to develop antibodies against this moiety. This was apparent based on the pre-dose positive samples across each of the 3 studies. Table 27 summarises the pre-dose ADA-positive samples across the studies.

The proportions of samples that were ADA-positive were similar in the MYL-1401H and EU-Neulasta groups (13.5% and 11.5%, respectively) but was quite low in the US-Neulasta group (4.1%), which appears to be a chance finding. Many of the subjects who were ADA-positive prior to dosing continued to remain positive throughout the study. The majority of these subjects had antibodies against the PEG moiety of the molecule.

<div style=\"page-break-after: always\"></div>

Table 27: Integrated summary of pre-dose immunogenicity results by sample (1001, 1002, 3001, ITT population)

| Parameter                     | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|-------------------------------|-------------|---------------|---------------|
| Total # of Samples            | 223         | 139           | 97            |
| Positive ADA samples pre-dose | 30 (13.5)   | 16 (11.5)     | 4 (4.1)       |
| PEG+ only                     | 14 (6.3)    | 13 (9.4)      | 3 (3.1)       |
| GCSF+ only                    | 2 (0.9)     | 0 (0.0)       | 0 (0.0)       |
| PEG+& GCSF+                   | 9 (4.0)     | 3 (2.2)       | 1 (1.0)       |
| PEG-& GCSF-                   | 5 (2.2)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

To assess the treatment-induced impact on immunogenicity, an analysis was conducted to evaluate the post-dose ADA-positive results excluding the subjects who were ADA-positive at baseline. The data at the sample and subject level is presented in Table 28 and Table 29.

Table 28: Integrated summary of post-dose immunogenicity results from subjects who were ADA-negative at baseline by sample (1001, 1002, 3001, ITT population)

| Parameter                      | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|--------------------------------|-------------|---------------|---------------|
| Total # of Samples             | 723         | 350           | 306           |
| Positive ADA samples post-dose | 36 (5.0)    | 22 (6.3)      | 44 (14.4)     |
| PEG+ only                      | 23 (3.2)    | 15 (4.3)      | 29 (9.5)      |
| GCSF+ only                     | 1 (0.1)     | 1 (0.3)       | 0 (0.0)       |
| PEG+ & GCSF+                   | 9 (1.2)     | 4 (1.1)       | 11 (3.6)      |
| PEG- & GCSF-                   | 3 (0.4)     | 2 (0.6)       | 4 (1.3)       |
| NAb+                           | 2 (0.3)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

Table 29: Integrated summary of post-dose immunogenicity results from subjects who were ADA-negative at baseline by subject (1001, 1002, 3001, ITT population)

| Parameter                      | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|--------------------------------|-------------|---------------|---------------|
| Total # of Subjects            | 192         | 123           | 93            |
| Positive ADA samples post-dose | 20 (10.4)   | 17 (13.8)     | 28 (30.1)     |
| PEG+ only                      | 13 (6.8)    | 13 (10.6)     | 20 (21.5)     |
| GCSF+ only                     | 1 (0.5)     | 1 (0.8)       | 0 (0.0)       |
| PEG+&GCSF+                     | 7 (3.6)     | 4 (3.3)       | 8 (8.6)       |
| PEG- & GCSF-                   | 3 (1.6)     | 2 (1.6)       | 4 (4.3)       |
| NAb+                           | 2 (1.0)     | 0 (0.0)       | 0 (0.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

<div style=\"page-break-after: always\"></div>

The data indicate that at the sample level, 5.0% and 6.3% of post-dose samples were treatmentemergent ADA-positive in the MYL-1401H and EU-Neulasta groups, respectively.

The proportion was higher (14.4%) in the US-Neulasta group. At a subject level, the proportions of subjects with post-dose treatment-emergent ADA-positive data were also similar for MYL-1401H and EU-Neulasta groups (10.4% and 13.8%, respectively), while it was 30.1% in the US-Neulasta group. Although the proportion of subjects who were treatment-emergent ADA-positive was higher in the USNeulasta group, the ADA in most cases were against only the PEG moiety, the titres were very low, and the antibodies were non-neutralizing. Only 2 subjects (1 each in the MYL-1401H and EU-Neulasta groups) had antibodies against the GCSF moiety only.

Two subjects were NAb-positive in the MYL-1401H group while none were NAb-positive in either Neulasta group. Table 30 presents the post-dose ADA-positive results excluding the subjects who were NAb-positive at baseline. This analysis is slightly different from analysis in Table 30 as it includes subjects who might have been ADA-positive but NAb-negative prior to dosing. The data indicate that there were 2 subjects who were treatment-emergent NAb-positive in the MYL-1401H group, 1 subject who was NAb-positive in the EU-Neulasta group, and 1 subject who was NAb-positive in the USNeulasta group.

Table  30:  Integrated  summary  of  post-dose  immunogenicity  results  from  subject  Nabnegative at baseline by subject (1001, 1002, 3001, ITT population)

| Parameter                         | MYL-1401H   | EU-Neulasta   | US-Neulasta   |
|-----------------------------------|-------------|---------------|---------------|
| Total # of Subjects               | 218         | 139           | 97            |
| Positive ADA Sample at least once | 26 (11.9)   | 21 (15.1)     | 31 (32.0)     |
| PEG+ only at least once           | 15 (6.9)    | 16 (11.5)     | 21 (21.6)     |
| GCSF+ only at least once          | 3 (1.4)     | 1 (0.7)       | 0 (0.0)       |
| PEG+ & GCSF+ at least once        | 8 (3.7)     | 6 (4.3)       | 11 (11.3)     |
| PEG-& GCSF- at least once         | 4 (1.8)     | 3 (2.2)       | 4 (4.1)       |
| NAb+ at least once                | 2 (0.9)     | 1 (0.7)       | 1 (1.0)       |

Abbreviations: ADA=antidrug antibody; NAb=neutralizing antibody

## 6.4.6. Laboratory findings

In study MYL-1401H-1002 all clinical laboratory parameters were measured at screening and followup, and each period at baseline on Day -1 and on Day 2. Absolute neutrophil count was also measured on Days 3, 8, 15, and 22 as part of the PD assessments. For both treatments, mean ALP and LDH levels on Day 2 of both periods were elevated compared with baseline but remained below the ULN. Also individual ALP and LDH levels during the study remained below ULN. In summary, all observed haematological and clinical chemistry changes were expected and were primarily related to the PD effects of pegfilgrastim.

## Summary of Haematology

Across all 3 studies (MYL-1401H-1001, MYL-1401H-1002, MYL-1401H-3001), there were no notable differences observed in the haematology measurements between the MYL-1401H groups and Neulasta groups. Across treatments, similar transient shifts in neutrophils and leukocytes occurred, and these parameters had returned to baseline levels by Day 13 and Day 15, respectively. White blood cell

<div style=\"page-break-after: always\"></div>

(counts of 100  10 9 /L or greater) have been observed in less than 1% of patients receiving Neulasta and are consistent with the PD effects of pegfilgrastim.

## Summary of Liver and Kidney Function Tests

Overall, there were no notable new differences observed in the liver or kidney function tests between MYL-1401H and Neulasta treatment groups. Liver function abnormalities are consistent with the PD effects of pegfilgrastim.

Vital signs, ECG, and physical findings in study 1002 can be summarised that they were insignificant for a population of healthy volunteers. There were no findings of splenomegaly or symptoms of splenic rupture during the physical examinations of the abdomen throughout the study. One subject (USNeulasta) had 'left side tenderness', which was considered to be of no clinical relevance.

Local tolerability (including ISR and VAS) in study 1002 was assessed each period at pre-dose and at 1, 4, 24 (Day 2), and 48 hours (Day 3) post-dose. Mostly, the ISR scores were 'none' (0). For 9 subjects that received MYL-1401H, at 1 or more time points following drug administration, a mild reaction was observed (ISR score of 1). This was mainly at 1 hour post-dose, but in some instances also at 4, 24, or 48 hours post-dose. For 5 subjects that received US-Neulasta, at 1 or more time points following drug administration, a mild reaction was observed (ISR score of 1). This was mainly at 1 hour post-dose, but in some instances also at 4, 24, or 48 hours post-dose. Most subjects had a score of 0 mm on a 0-100 mm VAS scale, indicating no pain at the injection site. There were 2 scores of 7 mm, all other scores were 4 mm or lower. The difference in the frequency of injection site reactions (ISR) 9/25 (36%; MYL-1401H) vs. 5/25 (20%; US-Neulasta) could reach statistical significance (not statistically analysed by the applicant). In trial 1001 identical but in 1002 different syringes were used. A higher frequency of injection site reactions (9/25 MYL-1401H vs 5/25 USNeulasta) has been observed and is noticeable in trial 1002 (all grade 1) but absent in pivotal 3001.

## 6.4.7. Post marketing experience

N/A

## 6.4.8. Safety related to drug-drug interactions and other interactions

N/A

## 6.4.9. Overall discussion and conclusions on clinical safety

## 6.4.9.1. Discussion

To assess clinical safety of Vivlipeg to be biosimilar to Neulasta (EU) based on the dossier submitted has several challenges.

Trial MYL-1401H-1001, has a cross-over design and therefore mainly period 1 can contribute to immunogenicity and safety assessment. For immunogenicity, results at the end of period 1 suggest that MYL-1401H is comparable to the reference product.

Trial MYL-1401H-1002, in healthy volunteers was specifically dedicated to investigate immunogenicity. Healthy subjects are in fact considered a more sensitive model to compare immunogenicity of two pegfilgrastims than immunosuppressed patients, although differences in the frequency of AEs have to be large to be detected in a small trial such as 1002. The confirmatory assay for ADA was positive at 1 or more time points for 8 of 25 (32.0%) subjects who received MYL-1401H and for 8 of 25 (32.0%) subjects who received Neulasta suggesting comparable immunogenicity of both products. Of note, this

<div style=\"page-break-after: always\"></div>

study used US-sourced Neulasta. The data are however relevant for the present application since an analytical bridge has been established between EU- and US-reference product.

Trial MYL-1401H-3001, a phase III trial with parallel group design comparing Fulphila with Neulasta EU sourced during 6 cycles of TAC showed similar ADRs that occurred at similar frequencies for Vivlipeg and Neulasta.

Overall, the AE profile of test and reference appeared similar. There is a high frequency of injection site reactions for MYL-1401H in study 1002. The relative high frequency of injection site reactions (grade 1) in the MYL-1401H arm of trial 1002 was an isolated finding in the smallest clinical trial and hence is not clinically relevant.

Immunogenicity data derived from the 3 studies suggest similar immunogenicity profiles of test and EU reference. In the integrated analysis, immunogenicity appeared to be higher with US-reference which may be due to the fact that US-Neulasta was only administered to healthy subjects that are more likely to mount an immune response to an antigen than immunocompromised patients on chemotherapy as treated in study 3001. Most of the ADA positivity, including that at predose, was directed against the PEG moiety of the molecule across the 3 groups, which is unsurprising as it is known that exposure to PEG-containing chemicals in the environment may lead to development of antibodies against this moiety.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 6.4.9.2. Conclusions on clinical safety

Overall, the results from the 3 clinical studies did not show any relevant difference in ADRs or immunogenicity compared to Neulasta. The safety of Vivlipeg supports the claim for similarity with Neulasta.

<div style=\"page-break-after: always\"></div>

## 7. Risk management plan

## 7.1. Safety specification

## 7.1.1. Proposed safety specification

The applicant proposed the following summary of safety concerns in the RMP:

Table 31: Summary of safety concerns

| Summary of safety concerns   |                                                                                                                                        |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Capillary leak syndrome Acute respiratory distress syndrome Sickle cell crisis in patients with sickle cell disease Glomerulonephritis |
| Important potential risks    | Cytokine release syndrome                                                                                                              |
| Missing information          | None                                                                                                                                   |

## 7.1.2. Discussion on proposed safety specification

The proposed safety concerns are in line with those of Fulphila and the reference product Neulasta and are considered acceptable.

## 7.2. Pharmacovigilance plan

## 7.2.1. Proposed pharmacovigilance plan

The applicant only proposed routine pharmacovigilance activities.

Routine pharmacovigilance activities beyond ADRs reporting and signal detection:

Specific adverse reaction follow-up questionnaires for:

- Capillary leak syndrome
- Cytokine release syndrome

to further characterise the events in the post-marketing setting.

The forms are provided in Annex 4 - Specific Adverse Drug Reaction Follow-up Forms of the RMP.

The applicant did not propose any additional pharmacovigilance activities.

## 7.2.2. Discussion on the pharmacovigilance plan

## 7.2.2.1. Routine pharmacovigilance activities

Routine pharmacovigilance activities are sufficient to address the safety concerns of this medicinal product. The proposed pharmacovigilance plan is in line with that of the reference product Neulasta.

Routine pharmacovigilance also remains sufficient to monitor the effectiveness of the risk minimisation measures.

<div style=\"page-break-after: always\"></div>

## 7.2.2.2. Additional pharmacovigilance activities

No additional pharmacovigilance activities proposed, which is considered acceptable.

## 7.3. Plans for post-authorisation efficacy studies

None. This is in line with the reference product Neulasta.

## 7.4. Risk minimisation measures

## 7.4.1. Proposed risk minimisation measures

## Table 32: Description of routine risk minimisation measures by safety concern

| Safety concern                      | Routine risk minimisation activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Capillary leak syndrome             | Routine risk communication: SmPC sections: 4.2, 4.4 and 4.8. Routine risk minimisation activities recommending specific clinical measures to address the risk: In Section 4.4, warning that capillary has been reported after granulocyte- colony stimulating factor administration, description of the key symptoms of this disorder and recommendation to closely monitor and treat affected patients if symptoms develop. Other risk minimisation measures beyond the Product Information: Follow-Up form (Annex 4) Medicine's legal status: Prescription-only medicine. Restricted medical prescription: The SmPC advises in Section 4.2 that therapy should be initiated and supervised by physicians experienced in oncology and/or haematology. |
| Acute respiratory distress syndrome | Routine risk communication: SmPC sections: 4.2, 4.4. and 4.8. Routine risk minimisation activities recommending specific clinical measures to address the risk: In Section 4.4, warning that pulmonary adverse reactions, in particular interstitial pneumonia, have been reported and that patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk. Other risk minimisation measures beyond the Product Information: None Medicine's legal status: Prescription only medicine.                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                                         | Restricted medical prescription: The SmPC advises in Section 4.2 that therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sickle cell crisis in patients with sickle cell disease | Routine risk communication: SmPC sections: 4.2, 4.4. and 4.8. Routine risk minimisation activities recommending specific clinical measures to address the risk: In Section 4.4, warning that sickle cell crises have been associated with the use of pegfilgrastim in patients with sickle cell trait or sickle cell disease and advice for caution (to be attentive to the possible association of this medicine with splenic enlargement and vaso-occlusive crisis) and appropriate monitoring when prescribing the product to such patients. Other risk minimisation measures beyond the Product Information: None Medicine's legal status: Prescription-only medicine. Restricted medical prescription: The SmPC advises in Section 4.2 that therapy should be initiated and supervised by physicians experienced in |
| Glomerulonephritis                                      | Routine risk communication: SmPC sections: 4.2, 4.4. and 4.8. Routine risk minimisation activities recommending specific clinical measures to address the risk: In Section 4.4, warning on glomerulonephritis reported with pegfilgrastim use and recommendation for urinalysis monitoring. Other risk minimisation measures beyond the Product Information: None. Medicine's legal status: Prescription-only medicine. Restricted medical prescription: The SmPC advises in Section 4.2 that therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.                                                                                                                                                                                                                       |
| Cytokine release syndrome                               | Routine risk communication: SmPC section: 4.2. No further text in SmPC. Routine risk minimisation activities recommending specific clinical measures to address the risk:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| None Other risk minimisation measures beyond the Product Information: Follow-Up form (Annex 4). Medicine's legal status: Prescription-only medicine. Restricted medical prescription: The SmPC advises in Section 4.2 that therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

The applicant states that routine risk minimisation activities are sufficient to manage the safety concerns of the medicinal product. This is in line with the reference medicinal product Neulasta.

The applicant did not propose any additional risk minimisation measures.

## 7.4.2. Discussion on the risk minimisation measures

The PRAC having considered the data submitted was of the opinion that:

In line with the reference product the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

## 7.5. RMP summary and RMP annexes overall conclusion

The RMP Part VI and the RMP Annexes are acceptable.

## 7.6. Overall conclusion on the Risk Management Plan

The CHMP and PRAC consider that the risk management plan version 0.2 (dated 11-Jun-2025) is acceptable.

<div style=\"page-break-after: always\"></div>

## 8. Pharmacovigilance

## 8.1. Pharmacovigilance system

The CHMP considers that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 8.2. Periodic safety update reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

<div style=\"page-break-after: always\"></div>

## 9. Product information

## 9.1. Summary of product characteristics (SmPC)

## 9.1.1. SmPC section 4.1 justification

Same as for the reference product.

## 9.1.2. SmPC section 5.1 justification

Same as for the reference product.

## 9.2. User consultation

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Fulphila. The bridging report submitted by the applicant has been found acceptable.

## 9.3. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Vivlipeg (pegfilgrastim) is included in the additional monitoring list since it is a biological product.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

<div style=\"page-break-after: always\"></div>

## 10. Biosimilarity assessment

## 10.1. Comparability exercise and indications claimed

The claimed indication is identical to the reference product Neulasta: 'Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)'.

The claim of biosimilarity is based on comparative analytical, nonclinical and clinical data. Clinical studies supporting the application were carried out in healthy volunteers as part of the biosimilarity exercise as well as a phase III clinical trial in breast cancer patients.

## Quality:

Vivlipeg is a multiple of Fulphila. To establish biosimilarity of Fulphila to EU Neulasta on the quality level, a comprehensive analytical comparability exercise was performed comparing Fulphila to EU Neulasta. Up to 12 batches of Fulphila and up to 34 batches of EU Neulasta were included in the analytical similarity studies.

## Non-clinical:

The non-clinical data in support of Vivlipeg are identical to the non-clinical data of the Fulphila dossier, which have been assessed and authorised by the CHMP. No new non-clinical data has been submitted.

## Clinical:

The clinical data in support of Vivlipeg are identical to the clinical data of the Fulphila dossier, which have been assessed and authorised by the CHMP. No new clinical data has been submitted.

## 10.2. Results supporting biosimilarity

## From a quality perspective:

With respect to primary, secondary and higher order structures comparability of Fulphila with the reference product EU Neulasta has been confirmed. Fulphila has been demonstrated to have an overall similar purity and impurity profile compared to Neulasta which refers in particular to oxidised and reduced, deamidated and charged variants, dimers, di-PEGylated variants and aggregates of pegfilgrastim as well as free filgrastim.

In addition, analytical similarity of Neulasta sourced from US and EU was established.

## From a non-clinical perspective:

No new non-clinical data have been performed/submitted.

## From a clinical perspective:

No new clinical data have been performed/submitted for this procedure.

With the previous application (EMEA/H/C4915) the applicant provides study results from 3 clinical trials, of which MYL-1401H-1001 is the pivotal PK/PD study.

MYL-1401H-1001 was a single centre, randomised, double-blind, 3-period, 3 treatments, 3-way crossover trial to evaluate the PD, PK, safety and tolerability of pegfilgrastim from test product (MYL1401H) compared to reference products EU- and US-Neulasta in healthy subjects. Primary objectives

<div style=\"page-break-after: always\"></div>

were comparison of PK and PD profiles after a single injection of a 2 mg dose of MYL-1401H and a single injection (2 mg) of EU- and US-Neulasta.

Trial MYL-1401H-1002 was a single-centre, randomised, open-label, repeated dose, parallel group trial intended to evaluate immunogenicity, PD, safety, and tolerability of the test product, MYL-1401H, compared with the reference product, US-licensed Neulasta. Healthy subjects received 2 single SC injections of 6 mg of either the test product, MYL-1401H, or the reference product, US-Neulasta, in 2 separate periods with a washout period of 4 weeks between study drug administrations.

The phase III trial MYL-1401H-3001 was a multicentre, randomised, double-blind, therapeutic equivalence study in breast cancer patients receiving 6 cycles TAC for adjuvant or neo-adjuvant treatment. The primary objective of the study was to compare the efficacy of MYL-1401H versus Neulasta during chemotherapy cycle 1 using duration of severe neutropenia (DSN), defined as days with ANC &lt; 0.5  10 9 /L, as endpoint.

##  Pharmacokinetics and Pharmacodynamics

- Study MYL-1401H-1001 demonstrated similar PK profiles of Neulasta-EU sourced, Neulasta-US sourced, and MYL-1401H (in all comparison-pairs).
- For the comparison test vs. EU reference, the 90% CIs of the primary PK endpoints Cmax and AUC0-inf ([0.984; 1.16] and [0.979; 1.12], respectively] lay well within the predefined acceptance range of 0.8 to 1.25.
- The PD profiles were also similar between the 3 treatments.
- For the comparison test vs. EU reference, the 95% CIs of the primary PD parameters ANC Cmax and ANC AUC0-t ([0.960; 1.028] and [0.959; 1.045], respectively) were well contained within the predefined equivalence range of 0.8500 - 1.1765. Also the 95% CIs of the secondary PD parameters CD34+ Cmax and CD34+ AUC0-t met these margins, further supporting biosimilarity.
- The PD parameters of all three products tested demonstrate that they are equivalent in terms of PD.
- Although study MYL-1401H-1001 was not powered to evaluate equivalence of the primary PD parameters for ANC in a smaller subgroup of ADA negative subjects, these results indicate that the primary PD parameters continued to be similar between MYL-1401H and the reference treatments EU-Neulasta and US-Neulasta in a subgroup of subjects without any ADA positive response at any time point. Also the secondary PD parameters appeared to be similar between MYL-1401H and the reference treatments in this subgroup.
- There were no clinically relevant differences in immunogenicity as shown in the trial MYL1401H-1002 where there were no detectable neutralizing antibodies detected.
- A secondary PD endpoint, however, was ANC which was descriptively analysed and supported the primary endpoints (Cmax and AUC of ANC) as of trial MYL-1401H-1001. The study 1002 is considered supportive of the overall biosimilarity of Fulphila

##  Efficacy

- Trial MYL-1401H-3001 met its primary objective. The mean ( SD) DSN in the MYL-1401H group was 1.2 ( 0.93), the median DSN was 1.0, and the DSN ranged from 0 to 5 days. In the EU-Neulasta group, the mean ( SD) DSN was 1.2 ( 1.10), the median DSN was 1.0, and the DSN ranged from 0 to 4 days. The 95% CI (-0.285, 0.298) for the difference

<div style=\"page-break-after: always\"></div>

- Safety
- The safety and immunogenicity profiles of MYL-1401H and EU-sourced Neulasta appeared generally similar in all 3 studies. The applicant presented within this application an integrated immunogenicity analysis which provided supportive evidence on the similarity of the immunogenicity profile.

## 10.3. Uncertainties and limitations about biosimilarity

There are no remaining uncertainties and limitations that have an impact on the conclusion of biosimilarity of Vivlipeg and Neulasta.

## 10.4. Discussion on biosimilarity

Analytical similarity of Vivlipeg to the reference product Neulasta (EU) has been shown in a satisfactory manner. Likewise, analytical similarity of Neulasta sourced from EU and US was also demonstrated. Therefore, results obtained in comparison to US-reference product can be bridged and are relevant in supporting the overall biosimilarity exercise in this application.

## Non-clinical

In vitro assays are considered more sensitive than in vivo studies to detect potential differences between test and reference product and hence, the results have shown equivalent similarity between the two products. Results from the in vitro study support a conclusion of functional similarity. The in vivo studies can be considered supportive of the biosimilarity.

## Clinical

The clinical pharmacology studies have shown that the PK and PD data were within the acceptance range for the criteria for biosimilarity and immunogenicity was comparable between Vivlipeg and Neulasta. In addition, the clinical efficacy and safety data support the claim for biosimilarity as demonstrated by showing equivalent DSN and rates of febrile neutropenia as well as comparable safety profiles between the two products.

Therefore, considering the totality of the evidence on the quality, non-clinical and clinical data, biosimilarity of Vivlipeg with the reference product EU Neulasta can be concluded.

## 10.5. Extrapolation of safety and efficacy

N/A

in least square mean DSN of MYL-1401H and EU-Neulasta was found to be within the prespecified equivalence range of [-1 day, +1 day].